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Abstract
Mass spectrometry coupled with liquid chromatography and gel electrophoresis enables separation and
detection of components in a complex mixture. During the last two decades, its applications were
dramatically extended and remarkable progress has been made in many fields, in particular,
environmental and biological analyses. This dissertation focuses on identification and characterization of
biologically active compounds and comparative analysis of protein expression changes.

The first two projects (Chapters 2 and 3) focus on the application of LC/MS approach to profile the
bioactivated intermediates of 4,4’-methylenedianiline (DAPM) from rat vascular smooth muscle cells
(VSMCs) and bile. In our study, several DAPM metabolites were detected and characterized in detail by
liquid chromatography-electrospray tandem mass spectrometry. The structural assignments of these
metabolites from VSMCs and rat bile significantly improve our understanding of DAPM
biotransformations and toxicity.

The third project described in Chapter 4 focuses on using electrospray tandem mass spectrometry
(ES-MS/MS) and theoretical calculation (GAUSSIAN 03 program) to investigate the unusual methyl
radical loss and consecutive fragment ions that dominate the low-energy collision induced dissociation
(CID) mass spectra of prodiginine compounds. Structures of the fragment ions are proposed and
explanations are given to rationalize the observed competition between the formation of even-electron
ions and radical ions. Our study shows that the lower apparent threshold associated with methyl radical
loss points to a lower kinetic barrier.

In Chapter 5, hypoxia-induced changes of zebrafish skeletal muscle were studied using two-dimensional
difference in-gel electrophoresis (2D-DIGE) in vivo after 48 h in hypoxia vs. normoxia. The results
showed that proteins involved in mitochondrial oxidative metabolism are down-regulated, whereas

ix

glycolytic enzymes are up-regulated to compensate for the loss of ATP synthesis in aerobic metabolism.
The up-regulation of two spots identified as hemoglobin variants was also observed. These protein
expression changes are consistent with a hypoxic response that enhances anaerobic metabolism or O2
transport to tissues.

Key words: Mass Spectrometry, NMR spectroscopy, Liquid Chromatography, Two-dimensional
Polyacrylamide Gel Electrophoresis, Metabolite Profiling, Proteomics, Methylenedianiline, Prodiginine,
Hypoxia, Zebrafish
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Chapter 1

Introduction

Introduction to Mass Spectrometry
During the last decade, mass spectrometry has played an important role in life science particularly for
protein characterization and identification. Advances in ionization of biological molecules and
complementary fragmentation techniques such as collision induced dissociation (CID),1, 2 electron capture
dissociation (ECD),3, 4 and electron transfer dissociation (ETD)5, 6 for peptides and proteins contribute to
structural elucidation and sequence determination. Advances in ionization source configuration and
electronic lenses in a new generation of mass spectrometry instruments led to significant improvements in
detection.
The principle of mass spectrometry is to ionize molecules, separate the gas-phase ions and detect them
according to their mass to charge ratios (m/z). There are different types of ionization sources, mass
analyzers and detectors. Magnetic deflection, quadrupole filter, ion trap, time of flight and ion cyclotron
resonance are the most commonly used techniques for mass analysis. Various types of mass spectrometry
coupled with liquid chromatography or electrophoresis are suitable for different purposes of analyses.
Presently, two ionization methods, matrix assisted laser desorption7 (MALDI) and electrospray8 (ES)
ionization, have led the main stream in ionization of biomolecules, providing sensitive and soft-ionization.
After nonvolatile biomolecules are ionized via protonation/deprotonation, the ions are sent and mass
resolved in different types of mass analyzers, for example a magnetic sector, quadrupole, time-of-flight
(TOF), quadrupole ion trap, linear ion trap, fourier transform ion cyclotron resonance9 (FTICR) mass
spectrometer.10 Finally the ions are detected by a dynode/electron multiplier for quadrupole, ion trap and
magnetic sector instruments, and by a multi-channel plate for TOF instruments, or image current for
FTICR and Orbitrap11 instruments. The performance of mass spectrometers is dependent upon ionization
efficiency of the target compounds, ion transmission through ion optics, collision processes and
sensitivity of detection. In the work that leads to this dissertation, several different types of mass
spectrometers were utilized to obtain the data.
Mass spectrometry has conventionally been used with gas chromatography (GC) to study the vaporized
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organic components eluted from GC column. In the combined GC-MS technique, molecular weight, plus
the identity could be obtained from the fragmentation pattern of the component, and the approach also
served as a basis to construct a library of compounds for structural identification. GC separation of the
sample is essential because tandem mass spectrometry isn’t widely applicable to GC-EI-MS, and without
it, the fragments from co-eluting compounds will interfere with identifications. However, many polar
compounds can’t be vaporized in GC, thus limiting the application of the technique.
During the last two decades, a great deal of progress has been made towards the analysis of biological
macromolecules when soft ionization techniques, especially ES and MALDI sources, were introduced as
new interfaces for mass spectrometers. The nondestructive nature of soft ionization has proven
advantages for the characterization of complex and polar substances that might be found in organic matter.
To apply the technology more effectively, it is important to understand the ionization process and
instrument configurations.

Electrospray ionization (ESI)
Several excellent reviews about the technology have been published.12, 13 In the electrospary process, high
voltage is applied between the solution and counter electrode to transform the solution into an electrified
mist, and form a shape of the spraying liquid named as the Taylor cone. Consequently, electrospray was
referred to as a neublization process instead of an ionization process. The mist consists of tiny droplets
containing solvent and analytes moving towards the counter electrode. Evaporation of solvent facilitates a
decrease in the size of droplets and an increase in charge repulsion on the droplet surface. High charge
density results in “columbic repulsion”, and further shrinks the droplets, and finally ejects the ions from
the droplets. The removal of solvent from the droplets could be assisted by a combination of heating
and/or gas flow. Desolvated ions are transferred into mass analyzer via ion optics. Although ES is already
a mature technique for ionization, there are still debates about the mechanism of ion formation.12
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Matrix assisted laser desorption ionization (MALDI)
In the MALDI process, sample is co-crystallized with a low molecular weight, UV-absorbing matrix that
enhances intact desorption and soft ionization of the analytes.14 A pulsed laser at a specific wavelength
absorbed by matrix is used to induce both desorption and ionization of the analytes. Meanwhile, ions
arising from the co-crystallized solid carry charges and even form dimers or multimers of the compounds
and tolerate a relatively high concentration of salts or buffers brought from biological experiments.14
Studies involving the energy transfer indirectly from a matrix to ionize the sample can be dated back to
the middle of 1980 by a beam of neutral atoms and molecules in fast atom bombardment (FAB-MS)15 or
by a flux of high energy photons in MALDI14. IR and UV laser sources have been used to ionize samples.
In MALDI, there are two observations obtained from different studies.7, 16, 17 In order to insure highly
efficient and well-controlled energy transfer to the sample, a resonance adsorption is required at the laser
wavelength. Secondly, to avoid the thermal decomposition of thermally labile compounds, each laser shot
should take place in a very short time interval. The recent development of atomospheric pressure MALDI
(AP-MALDI) doesn’t require a vacuum source, thus significantly increasing the throughput of analysis.18

Different Types of Mass Analyzers
In order to separate the complicated and limited amount of samples from biological sources, liquid
chromatography was coupled with electrospray mass spectrometer to obtain information about target
compounds. Three types of mass analyzers (quadrupole, quadrupole 3D ion trap, hybrid quadrupole/linear
ion trap) with ESI source have been mainly employed in metabolite profiling of the samples from rat
biliary effluent and vacular smooth muscle cells exposed to a low dosage of methylenedianiline, as well
as in the quadrupole ion trap protein identification using “bottom-up” strategy. The quadrupole ion trap
uses a combination of radio frequency and constant potential to store the ions in a potential well.19
Selected ions are either stored or ejected from the trap by changing the potentials depending on their
different m/z values. To obtain structural information, the stored ions can be analyzed to determine the
m/z value or further fragmented to form small fragments by ion-molecule collisions. Increasing the fill
4

time for the ion trap can enhance the sensitivity and resolution of mass peaks, however, space charge
effects are observed when high concentrations of ions are loaded into the trap, inducing ion repulsions
and limiting the mass accuracy and resolution.19 Auto gain control (AGC) was introduced to limit the
number of ions present in the trap by estimating the ion concentration with a rapid and “dirty” scan, and
then determining the fill time to maintain a certain amount of ions in the trap. The strategy not only
improved the sensitivity but also avoided space charge effects.20,

21

Up to now, it has been widely

employed in most commercial quadrupole ion trap mass spectrometry instruments.

Quadrupole Ion Trap
The quadrupole ion trap has two configurations: the two dimensional linear ion trap (2D LIT)22 and the
three dimensional ion trap (3D QIT)19, also named as “Paul Trap”. The former generally consists of two
hyperbolic cap electrodes facing towards each other and one hyperbolic ring electrode halfway between
them. A combination of AC and DC voltage on the trap can create a saddle-shaped field to trap the ions in
a complex motion. If ion excitation is desired, a sweep voltage is applied onto the two end cap electrodes
to empty the trap except for the selected ions. Then, an on-resonance radio-frequency voltage oscillates
between the two electrodes to increase the collisions between the ions and inert gas molecules to induce
fragmentation.19

Two-dimensional Linear Ion Trap (2D LIT)
The linear form of the ion trap can be used as a mass selective filter by creating a trapping potential well
along the axial electrodes.22 Advantages of the LIT includes a simple configuration, a fast scanning rate
and a larger trapping capacity than the 3D QIT. Although the trapping capacity of LIT has been improved
compared with that of QIT, the dynamic range of measurement is still the biggest limitation of ion trap
based mass spectrometry.22
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Schematic drawings of 3D quadrupole ion trap23

Triple Quadrupole
Another type of mass analyzer was built on three series of quadrupole mass analyzer, i.e. the triple
quadrupole. A quadrupole consists of four parallel rods on which a combination of rf and DC voltage was
applied. Scanning both rf and DC on the rods allows the quadrupole to act as a mass filter that allows only
certain m/z ions to be transmitted through the rods, and simultaneously other m/z ions will collide with
the rods. Based on this configuration, the triple quadrupole doesn’t trap the ions in a certain space, thus
avoiding the space charge effects occurring on the ion trap. The dynamic range of measurement is much
higher than both QIT and LIT. It has been widely used in quantitative analysis, however, because no time
is spent trapping the ions, the duty cycle of measurement is comparatively lower than that of the ion trap.
Thus, the sensitivity and mass accuracy of the triple quadrupole mass spectrometry are lower than those
of QIT and LIT. Triple quadrupole mass spectrometry is a typical space-based tandem MS in which it
selects the precursor ions in the Q1 and fragments them in the Q2 collision cell, and finally mass separate
the fragments in the Q3 mass analyzer.
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Schematic drawing of a single quadrupole mass filter
The electron multiplier is the last step in signal production. Transmitted ions are converted by multiplier
to a measurable current. Too low settings on multiplier will reduce the signal. In contrast, too high
settings will saturate the signal and reduce the lifetime of the detector, as well as give a poor quantitative
result.

TOF and TOF/TOF
In this dissertation, we used an ABI 4800 MALDI-TOF/TOF mass spectrometer to identify the proteins
regulated by hypoxia. In the TOF analyzer, ions formed in the pulsed ionization source are accelerated
with the same potential from a fixed starting line and at a fixed initial time and allowed to drift in a
field-free tube, the ions separate according to their m/z values. The time (t) that is required for the ions to
travel through the region is dependent of the m/z described in the equation below.

L is the length of the drift tube or the travel distance to reach the detector. To increase the resolving power
of the TOF mass analyzer, a reflectron TOF mass analyzer allows for energy focusing of the ions. In the
equation above, “L” represents the length of the drift tube, “m” the mass of the ions, “z” the charge of the
ions and “V” the potential applied to accelerate the ions into the drift tube. Lighter ions drift more quickly
to the detector, heavier ions drift more slowly.
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Schematic drawing of linear TOF mass spectrometry

Separation Tools (on-line or off-line) coupled with Mass Spectrometry
After over more than one century of development, separation science plays an active role in many fields:
organic synthesis for measuring purity and performing structural characterization of products; molecular
biology for sequencing the genome of human and other species; forensic science for analyzing the blood
and hair for criminal activities. Benefiting from the invention of capillary electrophoresis, the Human
Genome Project completed work much faster than was expected. The next challenging project demanding
the contribution of separation scientists is the analysis of the proteome, i.e., the complement of the
genome. Since the proteome is defined by a combination of the genome, the environment at the moment
and even cell history, cells do not have a fixed proteome. Instead, proteins are expressed with broad
dynamic range depending upon the particular characteristics of the cell. The combination of separation
science and mass spectrometry offers a promising future and resolution to these difficulties in proteomics
research. This dissertation focuses on the exploration of two most popular separation methods that were
readily available for on-line or off-line coupling with different mass spectrometers employed in my
studies. Additionally, the merits of LC/MS coupling are widely recognized for universality, high
sensitivity and outstanding selectivity in metabolite characterization. We used several LC/MS instruments
for determining the biotransformations of methylenedianiline in rat liver and vascular smooth muscle
cells.
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High Performance Liquid Chromatography (HPLC)
The combination of gas chromatography and electron ionization mass spectrometry still remains
unsurpassed for rapid separation and structural determination.24 However, not all the compounds can be
vaporized and ionized in GC/MS. The application of LC/MS allows the analysis of non-volatile samples.
However, this method has gone through some practical difficulties because of inefficient sample delivery
into the mass spectrometry before electrospray was introduced as a interface between LC and MS.
Among the forces driving the development of HPLC coupled with mass spectrometry, was the demand for
miniaturization of column size to improve the sensitivity and reduce sample consumption.25, 26 Increased
chromatographic resolving power and faster analysis by utilizing low volumes of stationary phase and
development of new chemical modified stationary phase to reduce “column bleeding” that primarily
produced the background noise were also primary concerns. Although most popular reports of LC-MS use
the ES source interface, off-line MALDI-ToF/ToF coupled with HPLC has continued to be improved for
proteomics work.27, 28

Two-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE)
Two-dimensional gel electrophoresis combines isoelectric focusing and mass separation steps to generate
a global view of the proteome in cells or tissue at a particular moment.29-31 With the utilization of different
visualization techniques such as radioactive labeling of protein, fluorescent dye labeling (CyDye),
fluorescent dye staining (commercial available products like Sypro Ruby, Deep Purple and Flamingo) and
non-fluorescence staining (silver or coomassie blue staining), one can visualize and quantify the protein
spots.
This technique enables identification of major proteins in tissue or sub-cellular fractions when it is
coupled off-line with mass spectrometry.32 In addition, 2D-PAGE have been used to quantitatively
determine the protein expression changes between two samples, such as a treated sample and the control.
However, quantitation was hampered by several factors. Low sensitivity and narrow dynamic range limits
the detection of the response of certain low abundance proteins that are critical in cellular functions.
9

Another technical issue is gel-to-gel variation. Practically speaking, there are no two gels that are
superimposable, which is required to overlay and compare them especially when significant proteome
expression changes occur or subtle proteome expression differences are under investigation.

2D Difference in-Gel Electrophoresis (2D-DIGE)33
2D-DIGE circumvents some these problems associated with traditional 2D-PAGE methodology. It utilizes
pre-electrophoretic labeled protein samples with one of three spectrally resolvable fluorescent CyDye
reagents (Cy2, 3 and 5), and Cy2 labeled protein as internal standard. These three CyDyes have similar
structures but distinct spectral properties. The samples can be imaged separately, and overlaid and
compared without warping since they come from the same gel.

488
482

Cy2

520

532
532

633

580

670

Cy3

Cy5

Schematic diagram of 2D-DIGE procedure and excitation and emission spectra of Cy2 , Cy3 and Cy5
(Adapted from GE health Science 2D-DIGE manual).
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The technique has a dynamic range that covers 5 orders of magnitude and nanogram level detection limits
that allow one to differentiate subtle, low abundance protein expression changes. DIGE does not require
modifications of the sample preparation protocol that is used in the conventional 2D-PAGE technique.

Applications of Mass Spectrometry
Identification and Characterization of Metabolites
All organisms are exposed to foreign compounds, i.e., to xenobiotics. The absorption routes could be
through the skin, lungs, or gastrointestinal tact. Elimination of these potential toxins usually relies on
biotransformations into non-toxic and hydrophilic chemicals that are readily for excretion. Without
biotransformation, lipophilic xenobiotics would only be eliminated very slowly out of the body. Studies of
the biotransformations of certain xenobiotics can assist the understanding of their toxicity upon exposure.
Biotransforming reactions are divided into two groups, named as phase I and phase II.34 Phase I includes
hydrolysis, reduction and oxidation; during the process some functional groups can be introduced
including –OH, -NH2, -SH or –COOH.34 Phase II reactions involve conjugations with the functional
groups previously introduced during phase I reactions such as glucuronidation, sulfonation, acetylation,
methylation, fatty acid, glutathione and amino acid conjugation.34 Most of phase II biotransformations
increase the hydrophilicity, thus greatly promoting the excretion of xenobiotics. Some exceptions to this
rule like fatty acid conjugation were found to significantly increase the lipophilicity that plagued the
elimination of toxins like aniline. 35
Glucuronidation is one of the major phase II biotransformations where glucuronic acid is attached to a
hydroxyl or carboxylic group (defined as O-glucuronidation); as well as N-glucuronidation is also
possible.34 The product of O-glucuronidation with phenols or alcohols is an ether glucuronide, while that
formed with carboxylic acid is an ester glucuronide. Gluronides are polar and water soluble conjugates
that are readily eliminated from the body in bile or urine. The substrates for N-glucuronidation include
primary and secondary aromatic and aliphatic amines. To quickly identify the glucuronides of xenobiotics,
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some characteristic neutral fragments (e.s. neutral loss of 176 Da, consecutive water losses from the
precursor ions) may appear in tandem mass spectra.
The substrates for acetylation are the xenobiotics containing an aromatic amine or a hydrazine group,
which form aromatic amides and hydrazides, respectively.36 However, acetylation replaces the amine with
a nonionizable group, which decreases the solubility of the metabolites. This process is catalyzed by
N-acetyltransferase and also requires the cofactor acetyl-coenzyme A.36 Thus, the conjugates may be
more toxic than their precursor, and conjugation does not improve the excretion of phase I metabolites. In
the mass spectra of acetyl conjugates, protonated or deprotonated molecular ions showed 42 Da increase
as compared to their non-conjugated metabolites. During the fragmentation, acetyl-ketene loss (42 Da) is
observed in CID-MS/MS spectra. For example, biotransformations of glutathione adducts lead to cysteine
conjugates that are followed by N-aceytlation,36 which typically show 42 Da loss in MS/MS spectra.
Amino acid conjugations are also observed, which results in a further increase in the solubility of phase
I metabolites. There are two possible pathways for the conjugation with either the xenobiotics containing
a carboxylic acid functionality or phase I metabolites including the hydroxylamine group. Amide bond
cleavage is dominant in the tandem mass spectra of the conjugates while other consecutive losses of water
(18 Da) and/or CO (28 Da) are present in lower abundance. We reported that a metabolite resulting from
glycine conjugation with DAPM hydroxylamine intermediate lost CO2 (44 Da) following the loss of NH3
(17 Da). This characteristic loss of CO2 (44 Da) can be used to identify amino acid conjugation with an
activated intermediate containing a hydroxylamine group.
The tripeptide glutathione containing nucleophilic cysteinyl thol group is present in millimolar
concentration in cells of most animals, which allows formation of glutathione adducts with the
electrophilic reactive intermediates of xenobiotics. The process significantly increases the solubility of the
phase I metabolites, and affords detoxification. The glutathione conjugates are usually followed by
subsequent biotransformation, thus leading to either loss of glycine to form γ-glutamylcysteinyl
conjugates37 or loss of glutamic acid to form glycinylcysteinyl conjugates38.
Thus, identification and structural characterization of these metabolites are essentially critical to
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understanding the potential toxicity of drug candidates and other contaminating toxins. Detailed structural
characterization of metabolites, produced in vivo or in vitro, can be performed using a variety of
spectroscopic techniques. The combination of chromatographic techniques with mass spectrometry is
presently the most efficient and powerful tool to provide structural information of the metabolites in
biological fluids. However, mass spectrometry can not differentiate some configurational or
conformational isomers. Other spectroscopic tools like NMR or IR are still needed to determine these
structures.

Proteomics
In the 1970s and 1980s, most biologists placed their attention on Genomics and Genetic Engineering.39, 40
During the past two decades, however, there has been a renaissance in protein biochemistry because of
accumulation of genome sequence data housed in accessible databases. It is obvious that the sequencing
of the entire genome is less meaningful if the functions of the gene can’t be clarified; this pursuit is
named “functional genomics”.37 Determination of the functions of gene products (genome complement,
proteome) was thought to be an efficient way of finding prognistic markers (biomarkers) of diseases.41
Proteins are the ultimate determinant in cellular function; however, it also embodies high order of
complexity. There are several factors that determine the protein function, such as the primary amino acid
sequence, post-translational modifications (PTMs), three dimensional structures, and the formation of
protein complexes for certain cellular function. Accordingly, proteomics research aims to determine
protein structure, modifications, localization, protein expression changes upon environmental stimulation
or drug treatment, and protein-protein interactions.42, 43
The challenges of proteomics research currently lies on several aspects: (1) limited sample quantities and
lacking of a amplification tool comparable to PCR in genome studies, thus creating an urgent need for
high sensitivity tools for protein identification and characterization; (2) broad dynamic range of protein
abundance in cells, that requires analytical tools with comparable dynamic range for detection and
quantification; (3) more complex information than that of the genome built upon four-base units (A, G, C
13

and T), thus demanding methods to provide quantitative and structurally informative output.
With the development of soft ionization methods like ESI8 and MALDI,44, 45 mass spectrometry earned
the reputation for its high sensitivity, broad dynamic range of measurements, rich information obtained
from complementary fragmentation techniques like CID,45,

46

infrared multiphoton dissociation

(IRMPD)47, electron capture dissociation (ECD)48 and electron transfer dissociation (ETD)5. MS for
protein identification and quantitation relies on the digestion by sequence-specific proteases. Short
sequence peptide is more suitable for MS analysis and they fragment more readily to provide sequence
information. The application of nano-size HPLC columns and on-line coupling with mass spectrometry
enables the proteomic analysis of complex protein mixtures. However, after the proteins are digested,
some peptides are either lost during the sample preparation, or their response is suppressed by other easily
ionizable peptides. In order to fully characterize the protein of specific interest, the concept of “top-down”
proteomics was proposed48, 49. The application of electron capture dissociation allows fragmentation of the
whole protein with low-energy electrons in FT-ICR mass spectrometry,50 thus revealing the labile
modifications on the whole protein. Thus it has attracted much attention for labile PTM characterization.
It also can be used to investigate protein-protein interactions because non-covalent bonds often remain
intact after backbone dissociation.51 Low-energy electron capture dissociation provides extensive
sequence coverage,52 while high energy electrons give w or z ions from polypeptides, thus allowing one to
distinguish isoleucine and leucine.53
Until recently, 2D-PAGE or 2D-DGIE had been widely used in the investigation of global protein levels
and differences in protein composition between two related samples.41 This enables the display of
hundreds or thousands of protein spots in a 2D-PAGE; however, hydrophobic, extremely basic or acidic
proteins are difficult to analyze. MS provides a large amount of information on a small sample size in an
automated manner. However, the ion abundance of peptides relies on the ionization efficiency that is
related to ionic strength in sample, source temperature, neubulizing and drying gas flow rate and other
factors. Thus, relative quantitation using hydorgen/deterium (H/D) isotope tag labeling has been
developed to compare the protein expression levels. There are two approaches for peptide stable isotope
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labeling to compare differential expression of proteins between the samples: chemically tagging the
cysteine residue or N-terminal amino group of the proteins using ICAT54 or iTRAQ55 reagents; metabolic
incorporation, in which protein tagging is achieved by culturing the cells in the medium containing stable
isotope enriched amino acids like SILAC.56 Tissue culture cells are grown in a medium that is short of
certain essential amino acids, and then the amino acid is supplied in two forms: one containing the natural
abundance of isotopes and the other containing the stable labeling isotope. After several cell cycles, all the
proteins are tagged with the provided amino acids. After selection of candidate tryptic peptides for
quantitative measurements, further MS/MS experiment on these precursors can identify the protein using
either de novo peptide sequencing57 or searching against the available database58.
The activity of proteins is modulated through post-translational modification (PTM) such as
phosphorylation and uniquitinylation or through proteolytic cleavage. These PTMs result in a change in
the molecular mass of the amino acid residues, or constant neutral loss in tandem mass spectra.59 All these
properties allow efficient characterization of PTMs in the proteins using the LC-MS/MS approach.
Proteomics research will impose significant changes to scientific world, especially in the pharmaceutical
industry. Because most drugs inhibit the function of specific proteins, several strategies were successfully
developed that incorporate the drug candidate screens with proteomic readout. For example,
activity-based profiling identifies and quantifies the active proteases in a complex proteome (cells or
tissue) using a small chemical probe to covalently attach to the active site of proteases.60 Another
approach is to elute the proteins from an immobilized drug, making them available for proteomic study.61,
62

All the methodologies were developed in the last decade to successfully link many endogenous proteins

with drug candidates, rather than the current single drug-single target model.
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Chapter 2

Identification of Metabolites of 4,4'-Methylenedianiline in Vascular Smooth
Muscle Cells by Liquid Chromatography-Electrospray Tandem Mass
Spectrometry

20

Abstract
A capillary liquid chromatography-electrospray tandem mass spectrometry (LC-ES-MS/MS) method was
developed for identification of metabolites of 4,4’-methylenedianiline (diaminodiphenyl methane, DAPM)
derived from exposure of

vascular smooth muscle cells to this compound. The use of precolumn

concentration and column switching techniques prior to reversed-phase liquid chromatography coupled
on-line to ES-MS enabled the separation and detection of low-level DAPM and its metabolites in the
exposed cell samples. The employed LC-ES-MS method, and further LC-ES-MS/MS analysis enabled
structural assignments for two DAPM metabolites from vascular smooth muscle cells: N-acetyl
methylenedianiline (N-acetyl DAPM) and N,N’-diacetyl methylenedianiline (N,N’-diacetyl-DAPM).
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Introduction
The aromatic amine 4,4’-methylenedianiline (DAPM, Figure 2.1) presents health hazards to animals and
humans, especially those working in industries that manufacture polymers. In recent years, DAPM has
been primarily used in the production of methylene diphenyl diisocyanate (MDI) and polymeric MDI,
which are employed in rigid and semi-rigid polyurethane fabrication. DAPM is also used to construct
numerous medical devices including catheters, dialysis tubing and surgical implants, and it can be
released during gamma-ray or autoclave sterilization of these devices [1]. Other DAPM derivatives are
used to make floor coverings, dye stuff intermediates, and a hardening agent for epoxy resins [2, 3].
Both occupational and accidental exposures to DAPM are known to cause fever, rash, toxic hepatitis and
jaundice with cholestasis and cholangitis [4, 5]. Hepatotoxic and carcinogenic effects in animals [6,7] and
human subjects [4,8] have also been documented, but the involved metabolic pathways and the
mechanism of toxicity are not clearly understood. Studies identifying DAPM metabolites in human urine
have revealed that acetylation is likely an important pathway in DAPM detoxification [9,10]. In addition,
prior reports examining the metabolism of DAPM in microsomal preparations revealed that it may
undergo oxidation to electrophilic azo and azoxy compounds[11].

In contrast, Kautiainen et al.[12]

demonstrated that the bulk of DAPM bound to hemoglobin in the blood existed in an imine form of
DAPM, likely derived from extra-hepatic sources of peroxidase enzymes. Thus, investigation of hepatic
metabolism of DAPM is probably insufficient for explaining its full array of toxicological effects.
T.R. Dugas et al. [13,14], reported that chronic, low-dose exposure to DAPM caused vascular toxicity in
rats that was more pronounced in females than in males.

The observed wall thickening of pulmonary

arteries was confined to the medial layer containing vascular smooth muscle cells (VSMC).

In addition,

the proliferative effects of DAPM could be reproduced in cultures of VSMC treated with DAPM [14].
Treatment of VSMC with [14C]-DAPM resulted in the disappearance of DAPM and the appearance of
several DAPM metabolites that were observed using HPLC with radioisotopic detection (unpublished
findings). Because direct treatment of VSMC with DAPM induced cellular proliferation, we hypothesized
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that VSMC may be capable of metabolizing DAPM to reactive intermediates that, in turn, bind to
molecular targets to promote VSMC proliferation. Importantly, no prior studies have reported on the
metabolism of DAPM by extra-hepatic cells, and few studies have investigated the metabolism of
xenobiotics by vascular cells.

Although VSMC are known to express the cytochrome P450 enzymes

CYP 1A1 and 1B1 [15] and are a rich source of the peroxidase enzyme prostaglandin H synthase, little
else is known about the ability of VSMC to metabolize xenobiotics. However, because the
biotransformation of DAPM by these cells is likely not as robust as that involving hepatocytes and
microsomes, development of a sensitive method for separating and characterizing DAPM metabolites
formed in VSMC was required and forms the basis for this paper.
Gas chromatography (GC) and liquid chromatography (LC) have been used for the separation of
metabolites of DAPM in urine and blood samples [16-21]. The low volatility of DAPM and its
metabolites necessitated a derivatization step [16] prior to GC separation coupled with electron capture
[17], thermionic specific [18], or mass spectrometric [19] detection. Derivatization is not required for LC
analyses employing ultraviolet absorbance (UV) [20], electrochemical [16] or mass spectrometric
detection [21].
On-line HPLC-plasma spray mass spectrometry and off-line fast atom bombardment tandem mass
spectrometry were used to study the metabolism of DAPM in rabbit hepatic microsomal incubation media,
and

three

metabolites

(4-nitroso-4’-aminodiphenylmethane,

azodiphenylmethane

and

azoxydiphenylmethane) were identified [21]. Compared to these older techniques, capillary (300 µm ID)
column LC-ES-MS can offer some performance advantages such as improved chromatographic
separation and lower detection limits. However, monitoring of DAPM and its metabolites in extracts from
vascular smooth muscle cells treated with low levels of DAPM can be rather challenging, and success in
characterizing metabolites will require high efficiency separations coupled with high sensitivity mass
spectrometric analyses.
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2.3 Experimental
Chemical and reagents
4,4’-Methylenedianiline (CAS No. 101-77-9; >97% pure), formic acid and ammonium acetate (CAS No.
631-68-3 >99% pure) were purchased from Sigma Chemical Co. (St Louis, MO). HPLC-grade
acetonitrile was purchased from EM Sciences (Gibbstown, NJ). Water was purified using a Milli-Q™
water system (Millipore Co, Billerica, MA).

14

C-DAPM was custom synthesized by American

Radiolabeled Chemicals (St. Louis, MO).

Sample Preparation and Handling
Manipulation of both DAPM and 14C-DAPM was performed in a hood using gloves and other protective
equipment. When working with radiolabeled compound, every precaution was taken to contain the
radioactivity. Upon completion of an experiment, all surfaces and glassware were decontaminated using
Rad-Con Surface Cleaner (Fluke Biomedical, Everett, WA). Vascular smooth muscle cells were isolated
from the aortas of male Sprague Dawley rats using a method described previously [14] . VMSC were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Mediatech, Herndon, VA) containing 10%
fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (Mediatech). For treatment with DAPM,
the cells were plated into 6-well tissue culture-treated plates. Once the VSMC had reached ~70-80%
confluence, the medium was aspirated, and the cells were treated for 24h with DMEM containing 10%
FBS and 3.57 µM DAPM. After treatment, the cells were removed from the plate by scraping in the
reaction medium, and the cell/medium mixture was homogenized using a Braun-Sonic U ultrasonicator
(Allentown, PA). Cell protein was then removed from the samples using Microcon (Millipore, Bedford,
MA) 10,000 M.W. cutoff centrifugal filters.

LC/MS/MS
LC analysis of DAPM and its metabolites was carried out on an “Ultimate” capillary/nano LC system (LC
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Packings Inc., San Francisco, CA, USA), which includes a “Switchos” advanced microcolumn switching
device. Separation was performed using a binary-gradient on a 300 µm I.D. × 15 cm, 3 µm, peptide map C18
reversed-phase column (LC packings, Amsterdam, Netherlands) with a mobile phase of: A) 15 mM ammonium
acetate buffer (pH 5.0) and B) acetonitrile, at a flow rate of 4 µl/min. The binary gradient went from 20% B
hold for 8 min (including pre-column concentration 5 min), then 20 to 38% B in 10 min, then 38 to 90% B in
20 min, and finally 90% B hold for 5 min. 20 µL of the sample was injected into the loop and loaded onto a
micro-precolumn (300 µm I.D. × 5 mm, C18), with 1% aqueous acetonitrile loading mobile phase. Separation
was enabled by the above-mentioned analytical column, with UV-detection at 254 nm, before the effluent was
electrosprayed on-line into the mass spectrometer.

On-line HPLC-MS detection was performed with a Micromass Quattro II triple quadrupole mass
spectrometer (Micromass Ltd., Cheshire, UK), equipped with an electrospray (ES) source. The
electrospray voltage used was 3.0 kV; cone voltage was set at 15 V, skimmer at 2 V, and the RF lens was
maintained at 0.3 V. The mass spectrometer was operated in the positive ion mode under unit-resolution
conditions. All parameters were initially tuned with a DAPM standard. Tandem mass spectrometric
analysis was performed with argon collision gas at a pressure of 2.0 x 10-4 mTorr (gauge external to
hexapole collision cell) and a collision energy of 30 eV.

Results and Discussion
The samples studied in this work are rat aortic smooth muscle cells that have been exposed to DAPM, and
a DAPM control sample that has had no cell contact. In view of the original concentration of DAPM (3.57
µM) used to initiate exposure of the cells, the concentrations of the metabolites and the remaining DAPM,
of course, are expected to be lower than 3.57 µM. The challenge presented by this project is to obtain
structural information concerning the bio-transformed metabolites that are present at extremely low
levels.
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LC/UV Chromatograms of the Sample and the Control Sample
The LC Packings Ultimate capillary HPLC features pre-column concentration and a column switching
technique [22-24], which can improve the detection limits. Large amounts of sample (up to 1 mL) can be
concentrated on the first 5 mm length C18 pre-column with simultaneous matrix removal (principally
de-salting), followed by elution of the concentrated sample onto the analytical reversed-phase C18
column for separation (Figure 2.2). Compared to direct injection, pre-column concentration allows
relatively large-volume sample injections, while maintaining narrow chromatographic peaks; sharper
peaks lead to higher signal-to-noise ratios. For our experiments that employed a single injection of 20 µL,
pre-column concentration enabled an improvement of the detection limits by a factor of ~ 20, relative to
what is obtainable via direct injection with no pre-column concentration. The number of effective plates
on the 15 cm length, 300 µm i.d. C-18 analytical capillary column is approximately 30,000.
When VSMC were exposed to 14C-labeled DAPM and the sample was extracted for analysis, there were
two major metabolite peaks appearing near that of the residual DAPM starting material. Comparison of
the LC/UV chromatograms obtained for DAPM exposure (Figure 2.3a) and no cell contact (control,
Figure 2.3b) shows that DAPM elutes from the column at 23.0 min, just after metabolite II at 22.0 min
(Figure 2.3a). The employed solvent gradient allowed baseline separation (thus minimizing the problem
of ionization suppression from coeluting species) and reasonably short (~25 min) retention times.
A comparison of the areas of the DAPM peaks in Figures 2.3a and 2.3b (DAPM with and without
vascular smooth muscle cell contact, respectively, all other experimental conditions identical) allows
calculation of the fraction of DAPM converted to metabolites:

DAPM fraction metabolized = 1 - [(Peak

Area of DAPM in the exposed cell sample) / (Peak Area of DAPM in the control)] = 1 - (24.7/35.3) = 1 0.70 = 0.30. Thus, 30% of the DAPM in the exposed VSMC sample was metabolized in 24 hr.
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Figure 2.2 Illustration of the column switching technique for pre-column sample concentration and
separation. (A)Sample is loaded from the loop onto the trapping column while the analytical column is
equilibrating. (B) Sample is desorbed from the trapping column in back flush mode and delivered through
the analytical column for separation while the next sample is loaded onto the loop. The LC effluent
passed through the UV detector and reached the mass spectrometer for detection.
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Figure 2.3 LC/UV chromatogram of (A) sample derived from vascular smooth muscle cells that have
been exposed to DAPM for 24 hr and (B) the control medium (no VSMC contact).
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LC/MS Chromatograms of the Sample and the Control Sample
A combination of two chromatographic detection systems resulted in the observation of many low
abundance signals in the investigated samples. A UV detector provides a signal based on the response of
chromophores within the compounds that absorb at the irradiation wavelength (254 nm). On-line coupling
of LC with an ES mass spectrometer can allow the differentiation of each compound by m/z value;
furthermore, structural information can be derived from tandem mass spectrometry (MS/MS)
experiments.
In the LC/MS chromatograms of both sample and control, a peak appears at about 24.9 min representing
protonated DAPM at m/z 199 (Figure 2.4c, 2.5c). Appearing only in the chromatogram of vascular
smooth muscle cells that have been exposed to DAPM is another peak at 24.1 min yielding a predominant
ion at m/z 241 (Figure 2.4b). Due to the conditions in our experiments, generated ions are in the form of
protonated molecules, [M+H]+, thus the molecular weight of the neutral molecule is 240 Da. This neutral
molecule that we are naming “Metabolite II” must contain an even number of nitrogen atoms according to
the nitrogen rule. The mass difference between DAPM and the heavier Metabolite II is 42 Da. The most
probable modification to DAPM to account for this mass increase is to add C2H2O (in preference to C3H6
or CH2N2); addition of C2H2O implies that one new unsaturation exists within the modification. The fact
that Metabolite II elutes prior to DAPM on the reversed-phase column indicates that this heavier DAPM
metabolite is more polar than the DAPM parent, and quells any speculation that a saturated -C3H7
functional group could have somehow replaced a proton on DAPM.
LC-ES-MS/MS employing collision induced dissociation (CID) was performed on DAPM and Metabolite
II. Figure 2.6 shows the product ion spectrum (with interpretation) of the residual DAPM starting material.
Figure 2.7 shows the product ion spectrum of protonated Metabolite II (m/z 241 precursor ion) revealing
a product ion at m/z 106, representative of an intact 4-methylene aniline portion within the metabolite,
and a second small peak at m/z 148. The assignment of m/z 106 was supported by the appearance of an
identical peak in the CID spectrum of the DAPM standard (Figure 2.6) and in other synthesized DAPM
metabolites (Nitroso, Azo, Azoxy, data not shown here). Metabolite II is assigned as the acetyl derivative
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of DAPM shown in Figures 2.4b and 2.7. Additional evidence for this structure is that the peak areas of
the later-eluting DAPM and the early-eluting Metabolite II are nearly the same in LC/UV, but the peak
area of the latter is only about one fourth of that of DAPM in LC-MS where the mass spectrometer is the
detector. A reduction in the ES ionization efficiency would be expected for the new amide linkage vs. the
original primary amino group, i.e., amide formation reduces ionization of the metabolite by ES. Clearly
the most probable site of acetylation is the amino group, thus forming N-acetyl-DAPM (Metabolite II).
Comparison between the LC-MS chromatogram of the sample derived from exposure of VSMC to
DAPM vs the control shows that a second metabolite appearing in the exposed cell sample (Figure 2.4) is
absent in the control (Figure 2.5). This metabolite, that we are naming Metabolite I, elutes at 23.5 min,
but because it was present in much lower abundance than Metabolite II, informative product ion spectra
could not be obtained. Metabolite I is assigned as a compound containing two acetyl groups linked to
DAPM, i.e., N,N’-diacetyl DAPM, and it was detected in protonated form at m/z 283. The fact that
Metabolite I elutes prior to Metabolite II in the reversed-phase chromatogram indicates that the former is
of increased polarity relative to the latter, which is consistent with the occurrence of a second acetylation.
Thus, Metabolite I is proposed to have undergone two acetylation reactions, i.e., one at each amino group
of DAPM (see Fig. 4a).
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Figure 2.4 LC-ES-MS of vascular smooth muscle cells sample that has been exposed to DAPM, A)
selected ion chromatogram of m/z 283; B) selected ion chromatogram of m/z 241; C) selected ion
chromatogram of m/z 199; D) total ion chromatogram.
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Figure 2.5 LC-ES-MS of the control sample with the same amount of DAPM (but no vascular cell
contact). A) selected ion chromatogram of m/z 283; B) selected ion chromatogram of m/z 241; C)
selected ion chromatogram of m/z 199; D) total ion chromatogram.
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Conclusion
A simple and sensitive LC-MS method utilizing pre-column concentration has been
developed to characterize low-level DAPM metabolites from vascular smooth muscle cells (detection
limit, S/N = 3, of ~ 500 nM in LC/MS and 2.5 nM in LC/UV). Simultaneous de-salting and concentration
utilizing column switching largely removes interferences present in the biological matrix, and thus,
significantly improves the ionization efficiency of the target molecules. LC-ES-MS/MS employing CID
of one metabolite (m/z 241 precursor) gave a product ion at m/z 106, representative of an intact
4-methylene-aniline portion within the metabolite. This assignment was supported by the appearance of
an identical peak in the CID spectrum of the DAPM standard. Based upon a combination of evidence
including m/z shifts, UV and ES responses, relative retention times, and interpretation of the product ion
mass spectrum, the m/z 241 metabolite was identified as protonated N-acetyl-DAPM. A second
metabolite, present in much lower abundance, was identified as N,N’-diacetyl-DAPM based upon its
relative LC retention, its MS spectrum, and its relative responses to UV and ES detection. The two
identifications support the notion that DAPM is unstable in the plasma of vascular smooth muscle cell,
and for detoxification, is readily transformed into metabolic products. Note that prior experimentation has
demonstrated that the employed dose (3.57 µM DAPM exposure for 24h) is not cytotoxic to the cells, and
the cellular response was increased proliferation and not cell death. Thus, the observed metabolism of
DAPM is not an artifact due to the presence of dead and dying cells.

36

References of Chapter 2
1.Shintani H, Nakamura A. Analysis of a carcinogen, 4,4’-methylenedianiline, from thermosetting polyurethane
during sterilization. J. Anal. Toxicol. 1989; 13: 354.
2.IARC. Chemicals used in plastics and elastomers. IARC Monogr. Eval. Carcinogen. Risk Chem. Hum. 1986; 36:
347.
3.Moore WM. Methylenedianiline.3ed. In Kirk-Othmer encylcopeida of chemical technologyMetylenedianiline Vol.
2, Mark HFDFO, Overberger CG, Seaborg GT (eds). John Wiley: New York 1978; 338.
4.Brooks LJ, Neale JM, Pieroni DR. Acute mycocardiopathy following tripathway exposure to methylenedianiline. J.
Am. Med. Assoc. 1979; 242: 1527.
5.Kopelman H, Scheuer PJ, Williams R. The liver lesion of the Epping Jaundice. Q. J. Med. 1966; 35: 553.
6.Pludro G, Karlowski K, Mankowska M, Woggon H, Udhe WJ. Toxicological and chemical studies of some epoxy
resins and hardeners. I. Determination of acute and subacute toxicity of phthalic acid anhydride,
4,4´-diaminophenylmethane and of the epoxy resin: epilox EG-34. Acta. Pol. Pharmaco. 1969; 26: 352.
7.Gohlke R, Schmidt P. 4-4'-Diaminodiphenyl methane, enzyme histochemical and autoradiographic investigations
in acute and subacute experiments in rats with and without the additional stress of heat. Int. Arch. Fur. Arbeitsmed.
1974; 32: 217.
8.Bastien PG. Occupational hepatitis caused by methylenedianiline. Med. J. Aust. 1984; 141: 533.
9. Cocker J, Boobis AR, Davies DS. Determination of the N-acetyl metabolites of 4,4'-methylene dianiline and
4,4'-methylene-bis(2-chloroaniline) in urine. Biomed. Environ. Mass Spectrom. 1988; 17: 161.
10. Robert A, Ducos P, Francin JM. Determination of urinary 4,4'-methylenedianiline and its acetylated metabolites
by solid-phase extraction and HPLC analysis with UV and electrochemical detection. Int. Arch. Occup. Environ.
Health 1995; 68(1): 44.
11. Kajbaf M, Sepai O, Lamb JH, Naylor S. Identification of metabolites of 4,4'-diaminodiphenylmethane
(methylene dianiline) using liquid chromatographic and mass spectrometric techniques. J.Chromatogr.1992; 583(1):
63.
12. Kautiainen A, Wachtmeister CA, Ehrenberg L. Characterization of hemoglobin adducts from a 4,
4'-methylenedianiline metabolite evidently produced by peroxidative oxidation in vivo. Chem. Res. Toxicol. 1998;
11(6): 614.
13. Dugas TR, Cruz VS, Liu H, Kanz MF. Evaluation of the gender differences in 4,4’-methylenedianiline toxicity,
distribution, and effects of biliary parameters. J. Toxicol. Environ. Health Part A 2001; 62: 467.
14. Dugas TR, Kanz MF, Hebert VY, Hennard KL, Liu H, Cruz VS, Conklin D, Boor PJ. Vascular medial
hyperplasia following chronic, intermittent exposure to 4,4'- methylenedianiline. Cardiovascular. Toxicol. 2004; 4:
85.
15. Zhao W, Parrish AR, Ramos KS. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in
human vascular endothelial and smooth muscle cells. In Vitro Cell Dev. Biol. Anim. 1998; 34(9): 671.
16.Peterson JC, Estiva EC, Lyttle DS. High-performance liquid chromatographic determination of 4,4,-methylene
dianiline in human urine. J. Chromatogr. 1991; 564(1): 205.
17. Tortoreto M, Catalani P, Bianchi M. Determination of 4,4´-diaminodiphenylmethane in blood by gas-liquid
chromatography with electron-capture detection. J. Chromatogr. 1983; 262: 367.
18. Skarping G, Dalene M. Determination of 4,4´-methylenediphenyldianiline (MDA) and identification of isomers
in technical-grade MDA in hydrolyzed plasma an urine from workers exposed to methylene diphenyldiisocyanate by
gas chromatography-mass spectrometry. J. Chromatogr. B 1995; 63: 209.
19. Cocker J, Boobis AR, Davies DS. Routes of activation of 4,4'-methylenebis-2-chloroaniline and
4,4'-methylenedianiline to bacterial mutagens. Food Chem. Toxicol. 1986; 24(6-7): 755.
20. Brunmark P, Persson P, Skarping G. Determination of 4,4´-methylenedianiline m hydrolyzed human urine by
micro liquid chromatography with ultraviolet detection. J. Chromatogr. 1992; 579(2): 350.
21. Kajbaf M, Sepai O, Lamb JH. Identification of metabolites of 4,4-diaminodiphenylmethane (methylene
dianiline) using liquid chromatographic and mass spectrometric techniques. J. Chromatogr. B 1992; 583(1): 63.
22. Van Soest REJ, Chervet JP. Ursem M, Suijlen JM. Analysis of fluorescence water tracers using on-line
perconcentration in micro HPLC. LC/GC International 1996; 9: 586.
23. Schaefer H, Chervet JP, Bunse C, Joppich C, Meyer HE, Marcus K. A peptide pre-concentration approach for
nano-high-performance liquid chromatography to diminish memory effect. Proteomics 2004; 4: 2541.
24. Choi SO, Um SY, Jung SH, Jung SJ, Kim JI, Lee HJ, Chung SY. Column-switching high-performance liquid
chromatographic method for the determination of zaltoprofen in rat plasma, J. Chromatogr. B 2006; 830(2): 301.
37

Chapter 3

Liquid Chromatography-Electrospray Tandem Mass Spectrometry
Investigations of Fragmentation Pathways of Biliary 4,4'-Methylenedianiline
Conjugates Produced in Rats
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Abstract
4,4’-methylenedianiline

(DAPM)

is

the

main

building

block

for

production

of

4,4’-methylenediphenyldiisocyanate that has been widely used in the manufacturing of polyurethane
materials including medical devices. Although it was revealed that damage to biliary epithelial cells of the
liver and common bile duct occurred upon acute exposure to DAPM, the exact mechanism of DAPM
toxicity is not fully understood. Both phase I and II biotransformations of DAPM, some of which
generate reactive intermediates, are characterized in detail by liquid chromatography electrospray tandem
mass spectrometry. The two most prominent metabolites found in rat bile (M2 and M7) implicated
glutathione, glucuronic acid and glycine conjugations (phase II) following hydroxylation, and
N-oxidation (phase I). Their decomposition pathways, as evidenced by MSn experiments, have been
elucidated in detail.
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Introduction
One class of xenobiotics that has attracted much attention for its potential toxicity is the aromatic amines.
Reports on toxic exposure to aromatic amines date back to the early 1900s.1 The most common threat
from those compounds results from accidental occupational and incidental environmental exposure.2 It
has been postulated3 that reactive intermediates of the starting materials are primarily responsible for the
toxicity, and that these activated forms bind with proteins critical to certain cellular functions. DAPM
(also known as 4,4’-methylenedianiline or diaminodiphenylmethene), is an aromatic diamine (Figure 3.1a)
of considerable industrial and commercial importance. It has been used as a chemical intermediate in
several syntheses, including certain isocyanates and polyurethane polymers. It has also been employed as
the cross-linking agent for epoxy resins, and as an antioxidant and curative agent in the preparation of azo
dyes and rubber products.4, 5
DAPM is an environmental contaminant which has potentially harmful effects on human and animal health.
Early documentation of DAPM hepatoxicity was established in a study of residents of Epping (England) who
had consumed DAPM-contaminated bread.6 Although it was revealed that biliary epithelial cells of the liver
and common bile duct could be injured upon acute exposure to DAPM,7, 8 the exact mechanism of DAPM
toxicity is not fully elucidated. Other studies have shown that DAPM is an animal carcinogen, and
histopathological abnormalities have been observed in the liver, kidney and lung of mice,9 although metabolic
pathways for bioactivation of DAPM have not yet been fully described.
With the introduction of various analytical techniques such as GC, HPLC and LC/MS, investigations of the
biotransformations of DAPM have grown. Acetylated metabolites were reported to be found in urine, blood
and vascular smooth muscle cells.10, 11 However, their presence cannot explain the toxicity of DAPM. Other
reactive and toxic metabolites are expected in bile, the likely route of exposure of bile duct cells to the
proximate toxicant. Hemoglobin adduction with DAPM after conversion of the latter to an imine form was
reported by Kautiainen and colleagues.12 This biotransformation of DAPM into a reactive imine was
speculated to be catalyzed by extrahepatic peroxidase enzyme. We recently reported the characterization of
biliary metabolites of DAPM using various spectroscopic techniques13. DAPM was found to be converted by
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Figure 3.1 (a) LC/MS total ion chromatogram (TIC) of biliary metabolites in a rat dosed with
methylenedianiline (DAPM); LC/MS reconstructed ion chromatogram of: (b) M2 at m/z 532; and (c) M7
at m/z 478
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phase I and II biotransformation generating N-oxidation, hydroxylation, acetylation, glucuronic acid and
glutathione conjugation products. The interesting biotransformations of these reactive and novel metabolites
prompted us to decipher their fragmentation pathways observed in tandem mass spectrometry experiments
under collision-induced dissociation (CID). Our assignments, and mechanistic interpretations of product ion
spectra of these DAPM metabolites should prove useful in future characterizations of other aromatic amine
metabolites.

Experimental Details
Animals
Bile duct-cannulated Sprague-Dawley rats were dosed with vehicle (ethanol) or 25/50 mg/kg DAPM; bile
was collected for 6 hours on ice and then stored immediately at -80 oC. To remove the protein, aliquots of
bile (20-50 µL) were thawed and filtered using Microcon 10,000 MW centrifugal filters (Fisher Scientific,
Houston, TX). Before the samples were injected into LC/MS, they were kept on ice.

Liquid Chromatography/Mass Spectrometry
The samples were separated on a reversed-phase HPLC column (Waters XTerra-MS C18, 1 × 150 mm, 3
µm) by a gradient solvent system consisting of solvents A (10 mM ammonium acetate pH 3.5) and B
(Acetonitrile). The percentage of mobile phase B was maintained at 15% for the first 2 min with the flow
rate set at 50 µL/min, and then ramped linearly to 35% over the next 33 min. The proportion of B was
increased to 90% over the next 15 min. Aliquots of filtered bile (20 µL) were injected onto the column
and directly delivered into the electrospray LCQ Deca Xp Plus mass spectrometer (Thermo-Finnigan, San
Jose, CA) that was operated in the positive ion mode. The metabolites were first detected in a LC-MS
survey scan, and the most abundant ion found during each survey scan was then selected to be fragmented
using the data-dependent acquisition mode. The six most abundant MS2 fragments were automatically
selected to acquire ensuing MS3 spectra. To cut down on redundant data acquisition, dynamic exclusion
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was enabled at the following settings: repeat counts = 2,

repeat duration = 0.3 min, exclusion duration

= 0.4 min, and exclusion mass width = 3 Da. The temperature of the ion transfer capillary was maintained
at 275 °C and the electrospray needle was operated at 3.2 kV. Tandem mass spectra were obtained with a
mass window of 3 Da, relative collision energy set at 38%, and an activation time of 5-30 msec.

Results and Discussion
As described previously,13 biliary metabolites of DAPM have been observed using LC-radioisotope
detection. Either off-line (fraction collection) or on-line LC/MS was carried out with mass spectrometric
characterization of the metabolites. M1-M9 appeared at m/z 375, 532, 403, 475, 24, 417, 478, 574 and
517 Da, respectively. Of the nine metabolites, M2 and M7 are the most intriguing and complicated
metabolites. Both involve N-oxidation and hydroxylation of the parent DAPM compound, along with
glutathione conjugation on M2, or glucuronic acid and glycine adduction on M7. Although structural
characterizations were accomplished on both metabolites via various spectroscopic techniques,13 their
detailed fragmentation mechanisms based upon MSn data are presented here for the first time.

Metabolite M2
During LC-MS analysis, M2 is observed as a protonated molecule [M+H]+ at m/z 532 with a retention
time of 7 min (Figure 3.1b). The product ion spectrum of M2 is shown in Figure 3.2a. Major product ions
of the protonated M2 precursor correspond to loss of the pyroglutamate moiety (-129) leading to the base
peak at m/z 403, or loss of the glycine moiety (-75), thereby generating a fragment ion at m/z 457. Those
neutral losses are characteristic of glutathione adducts during CID experiments. Two additional fragments
at m/z 308 and 179 correspond to protonated glutathione (thiol form) and protonated cysteinyl-glycine,
respectively. The appearance of these four characteristic fragment ions allowed the identification of M2 as
a GSH adduct. In addition, fragment ions at m/z 385, 439 and 514 were formed via H2O loss from m/z
403, 457 and 532, respectively. Glutathione conjugation is proposed to occur at the imine nitrogen atom
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Figure 3.2 (a) MS/MS spectrum of protonated M2 at m/z 532 and (b) MS3 spectrum of m/z 300; (c)
proposed fragmentation pathways of protonated M2 and m/z 300

44

based on the absence of an N-H proton and the presence of a full complement of aromatic ring protons
(i.e., 8) in the 1H-NMR spectrum. Assignment of the hydroxylated form of the DAPM methylene bridging
carbon resulting from phase I metabolism of the M2 precursor was deduced13 from 1H-NMR and TOCSY
spectra, and the predicted chemical shift of the hydroxyl proton calculated using Chemoffice Ultra 2004
software (Cambridgesoft Corporation, Cambridge, UK).
Even though solid evidence of glutathione conjugation was readily derived from LC-MS/MS, little
information about the xenobiotic moeity was directly obtainable from MS2 spectra because cleavages
occurred primarily at or on the GSH moiety. To enhance the amount of structurally-informative
fragmentation, the data dependent MS3 data acquisition method was employed on mass spectral peaks
appearing in the low m/z range (m/z 200-400) which represent fragments with charge retention on the
xenobiotic moiety. These informative fragments appeared at m/z 199, 225, 257, 283 and 300 in the
MS/MS spectrum (Figure 3.2a), and they were subjected to further fragmentation. The MH+-232 fragment
at m/z 300 (Figure 3.2c) was formed via

successive eliminations of pyroglutamic acid, glycine residues

and CO from protonated M2.14 A further elimination of NH3 led to the fragment ion at m/z 283 (Figure
3.2b). The fragment ions at 199, 225 and 257 were produced from the ion m/z 283 ion formed by the
cleavage of m/z 300 (Figure 3.2b); proposed fragmentation pathways are shown in the Figure 3.2c.
Additional fragments at m/z 132 and 197 were derived from MS3 decompositions of m/z 225 (Figure
3.3a), and the corresponding cleavage mechanisms are shown in the Figure 3.3c. The formation of m/z
197 is proposed to occur via rearrangement and elimination of CO (28 Da) with the driving force being
production of a highly resonance-stabilized ion shown in Figure 3.3c. The MS/MS spectrum of m/z 199
gave a fragment at m/z 106 (Figure 3.3b), representing the 4-nitrosophenyl moiety and thus presenting
evidence of N-oxidation at one amino group of DAPM. The above interpretation leaves the other
(non-nitroso) nitrogen as the only remaining site on M2 available for GSH adduction.
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Figure 3.3 MS3 spectra of the precursor ions at: (a) m/z 225; and (b) m/z 199 derived from protonated
M2 present in bile of a rat dosed with DAPM; (c) corresponding fragmentation pathways
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Metabolite M7

M7, eluting at an LC-MS retention time of 21 min (Figure 3.1c), appeared as the protonated molecule
[M+H]+ at m/z 478. In the MS/MS spectrum (Figure 3.4a), the protonated M7 precursor underwent a 176
Da (-anhydroglucuronic acid) loss characteristic of a glucuronide to generate the product ion at m/z 302.
H2O losses to form the fragment ions at m/z 460 (-H2O) and 442 (-2H2O) (Figure 3.4a) were also visible.
The MS3 spectrum of m/z 302 gave a product ion at m/z 285 corresponding to NH3 loss (Figure 3.5a). The
above mentioned characteristic glucuronide loss (-176 Da) could also occur in conjunction with NH3 loss
(-17 Da) from the m/z 478 precursor to give m/z 285 (Figure 3.4a), and the corresponding mechanisms
are proposed in Figure 3.4b. The MS3 spectrum of m/z 285 (Figure 3.5b) yielded: m/z 106, 136, 148, 150,
241 and 267. The fragmentation pathways leading to m/z 136 and 150 are shown in Figure 3.5e.

The monoisotopic mass of M7 appears at an even m/z value, indicating that it contains an odd number of
nitrogen atoms based on the “nitrogen rule”. The possibility of amino acid conjugation with one of the
free amines of DAPM can account for both the mass increase, and the addition of a third nitrogen. There
are two well-established metabolic pathways of amino acid conjugation with xenobiotics containing
primary aromatic amine functional groups. One is through reaction of the amino acid carboxylic acid
group with a free amine on the xenobiotic to form an amide bond, such is exemplified by glutamic acid
conjugation with acetaminophen metabolites.15 Secondly, xenobiotics containing a hydroxylamine group
may conjugate with the carboxylic acid group of amino acids such as proline or serine.16 This is
accomplished when aminoacyl-tRNA synthetase activates the amino acid and then conjugates it with
hydroxylamine to form an N-ester that can be degraded into an electrophilic nitrenium ion.17 The MS3
loss of 44 Da from the precursor ion at m/z 285 gave the product ion at m/z 241(Figure 3.5b), that we
have assigned as CO2 loss. Observation of this prominent CO2 loss indicates that an N-ester (-N-O-C(O)-)
had been formed rather than an amide (-N-C(O)-) bond (Figure 3.6). In our search of the literature, we
were unable to find previous examples of this type of glycine conjugation to aromatic hydroxyl amines
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(with glycyl- t-RNA synthetase participation). MS4 of m/z 241 gave the product ions at m/z 106 and 148
(Figure 3.5c), representing 4-nitrosobenzyl and its precursor (Figure 3.6). The appearance of m/z 106
indicated N-oxidation at the other free amine group of DAPM. The fragment ion at m/z 148 suggested
hydroxylation on the methylene bridging carbon of DAPM (Figure 3.6). Under CID, m/z 285 also
underwent H2O loss to form a fragment ion at m/z 267 (Figure 3.5b), corroborating the postulation that
hydroxylation had occurred on the methylene carbon. The MS4 spectrum of m/z 267 showed a fragment
ion at m/z 132 (Figure 3.5d), and the corresponding pathway is shown in Figure 3.6. Because both amine
groups of DAPM have been metabolized, the only reasonable site for glucuronic acid conjugation is with
the hydroxyl oxygen on the bridging carbon. Thus the structure of M7 can be confidently identified.

Conclusion
The structural assignments of these metabolites from rat bile are mainly based on LC-tandem mass
spectrometry data. MSn spectra up to MS4 were acquired for the thorough structural elucidation that forms
the basis for this paper. Detailed interpretation of MSn spectra is essential to eliminating ambiguity in
deducing metabolite structures. A combination of metabolic processes was involved in transforming
DAPM into the M2 and M7 metabolites found in rat bile. These biotransformations include glutathione,
glycine and glucuronic acid conjugation (phase II) of DAPM that had previously undergone
hydroxylation and N-oxidation (phase I). They demonstrate that DAPM is susceptible to (phase I)
conversion to electrophilic species that can be trapped by phase II metabolism. The existence of phase I
reactive metabolites of DAPM supports the postulation that reactive intermediates are involved in the
toxicity of DAPM, possibly implicating covalent protein adducts that were also found in rat bile.13 Further
studies are in progress to characterize those DAPM modified proteins.
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Figure 3.4 MS3 spectra of the precursor ions at: (a) m/z 225; and (b) m/z 199 derived from protonated
M2 present in bile of a rat dosed with DAPM; (c) corresponding fragmentation pathways
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Figure 3.5. MS3 spectra of: (a) m/z 302 and (b) m/z 285; MS4 spectra of: (c) m/z 241; and (d) m/z 267; (e)
proposed fragmentation pathways of m/z 285 leading to the fragment ions at m/z 136 and 150
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Figure 3.6 Proposed fragmentation pathways leading to the MS3 product ions at m/z 241 and 267, and the
MS4 product ions at m/z 106, 132 and 148
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Chapter 4

Unusual odd-electron fragments from even-electron protonated prodiginine
precursors using positive ion electrospray tandem mass spectrometry
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Abstract
Reports of anti-cancer and immunosuppressive properties have spurred recent interest in the bacterially
produced prodiginines. We use electrospray tandem mass spectrometry (ES-MS/MS) to investigate
prodigiosin, undecylprodiginine and streptorubin B (butyl-meta-cycloheptylprodiginine), and explore
their fragmentation pathways to explain the unusual methyl radical loss and consecutive fragment ions
that dominate low-energy collision induced dissociation (CID) mass spectra. Structures of the fragment
ions are proposed and explanations are given for the competition between the formation of even-electron
ions and radical ions. Theoretical calculations have been used to optimize the structures and calculate the
energies of both reactants and products using the GAUSSIAN 03 program. Results indicate that
protonation occurs on the nitrogen atom that initially held no hydrogen, thus allowing formation of a
pseudo-seven-membered ring that constitutes the most stable ground state [M+H]+ structure. From this
precursor, experimental data show that methyl radical loss has the lowest apparent threshold, but
alternatively, even-electron fragment ions can be formed by loss of a methanol molecule. Computational
modeling indicates that methyl radical loss is the more endothermic process in this competition, but the
lower apparent threshold associated with methyl radical loss points to a lower kinetic barrier. Additionally,
this characteristic and unusual loss of methyl radical (in combination with weaker methanol loss) from
each prodiginine is useful for performing constant neutral loss scans to quickly and more efficiently
identify all prodiginines in a complex biological mixture without any clean-up or purification. The
feasibility of this approach has been proven through the identification of a new, low abundance
prodigiosin analog arising from Hahella chejuensis.
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Introduction
Prodiginine analogs belong to a family of naturally occurring red-pigment antibiotics that are secondary
metabolites biosynthesized by many strains of Gram-positive and Gram-negative bacteria.1 These
compounds are characterized by a common pyrrolydipyrrolylmethene backbone and a methoxy function
on the B-ring (Scheme 4.1). The chemical composition of prodigiosin, a representative member of the
prodiginine family, was established half a century ago by chemical synthesis.2, 3 Other close analogs,
bearing the same skeleton but different alkyl substituents, have been reported,

such as

undecylprodiginine4, streptorubin B5, methylcyclodecylprodiginine6 and cycloprodigiosin7.
By virtue of their brilliant red color, these compounds were used as ink for a short time period prior to the
appearance of synthetic dyes8. The prodiginines are also antibiotics that have a broad range of activities
against bacteria, pathogenic fungi and protozoa, but they have not been widely employed in clinical trials
because of their toxicity.9, 10 Some studies have shown that their common skeletal features, e.g., the
presence of the B-ring C6-methoxy group (Scheme 4.1), are related to the cytotoxicity of prodigiosin; the
A-ring also plays an important role in nuclease activity and cytotoxic effects.11 The toxic effects were
speculated to arise from intercalation with DNA, leading to oxidative DNA cleavages in the presence of
O2 and Cu(II).12, 13 Although the exact cytotoxic mechanism was not completely clarified, some recent
findings have shown that prodiginine-type compounds are potent immunosuppressants at lower, non-toxic
levels, and slightly higher dosages can efficiently induce apoptosis of cancer cells with little toxic effects
on normal cell lines in vivo and in vitro.14, 15
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Scheme 4.1 Traditional structural representation of three investigated prodiginines: prodigiosin,
streptorubin B, and undecylprodiginine.
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Recent findings concerning their anti-cancer11, 16 and immunosuppressive properties14, 17, 18 have led to the
expansion of prodiginine studies. Intrigued by their pharmaceutical prospects, the total synthesis of
prodiginine-type compounds has been reported.19 Moreover, synthetic analogue named GX15-070 has
been used in phase I/II clinical trials for cancer treatment.20 However, other analogs anticipated to have
even more anti-tumor activity, such as streptorubin B (butyl-meta-cycloheptylprodiginine, Scheme 1),
were difficult to synthesize in the lab. Thus, a biosynthetic pathway might be a good alternative to
achieving rapid and cost-effective production of prodiginine-type drugs. To improve the understanding of
the biosynthesis of prodiginine antibiotics, studies have been completed to elucidate pathways in
Streptomyces

coelicolor

leading

to

key

intermediates

including

4-methoxy-2,2’-bipyrrole-5-carboxaldehyde (MBC)21 and 2-undecylpyrrole (UP)22.
Prodiginines show a characteristic brilliant red color and they readily absorb visible region light which
has been exploited for liquid chromatographic detection. Structural characterization has almost
exclusively relied upon NMR spectroscopy that requires relatively large sample quantities, as well as
labor-intensive purification steps. New developments in mass spectrometry over the last two decades have
earned it the reputation for offering high sensitivity, a wealth of structural information with the use of
complementary fragmentation techniques, and the ability to deal with complex mixtures. Up until now,
however, mass spectrometry has mainly provided molecular weight confirmation in prodiginine
identifications.
Understanding the major fragmentation pathways for prodiginines can help in the structural elucidation of
synthetic prodiginine analogs and novel prodiginines generated by biosynthetic processes. Generally, all
the prodiginine analogs are readily detected in the positive ion mode owing to available basic nitrogen
atoms, which enables one to gain important structural information without further purification, especially
if there are low abundance prodiginine analogs in a complex mixture. Our study investigates all the major
fragmentation mechanisms using multi-stage tandem mass spectrometry as well as theoretical
calculations.
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Experimental
Chemicals and Sample Preparation
Undecylprodiginine and streptorubin B were purified from Streptomyces coelicolor strains.
Undecylprodiginine was isolated from mycelia of S. coelicolor W31 which is unable to make streptorubin
B.23 Streptorubin B was isolated from S. coelicolor M511 which produces a mixture of
undecylprodiginine and streptorubin B. Mycelia were extracted with acetonitrile/methanol (50:50),
acidified with 2 N HCl (1%) and vortexed for 30 sec. One volume of chloroform and one volume of 1 N
HCl were then added to each volume of prepared extracts; and the chloroform fractions, which contained
prodiginine hydrochlorides, were recovered. The fraction originating from S. coelicolor W31 was washed
with 1 N NaOH to afford undecylprodiginine as a free base which was purified by flash chromatography
on basic alumina using 100% ethyl acetate as eluent. Undecylprodiginine appeared as a yellow pigment in
ethyl acetate. The chloroform fraction originating from S. coelicolor M511 was evaporated to dryness and
streptorubin B hydrochloride was purified by semi-preparative HPLC using an Agilent 1100 instrument
equipped with a quaternary pump and variable wavelength detector set at 533 nm. Extracts that were
resuspended in acetonitrile/methanol (50:50) were injected onto an Agilent C18 column (100 x 21 mm, 5
µm) using the gradient elution profile: water (adjusted to pH 3 with HCl)/acetonitrile 30:70 to 20:80 in 20
minutes at a flow rate of 5 µL/min; pure streptorubin B eluted after 8.2 min.
In separate experiments, prodigiosin and its analog were extracted from Hahella chejuensis culture with a
solvent of methanol containing 0.1 N HCl on a shaker for 2 hrs at 4 °C. The resultant mixture was
centrifuged at 4000 × g for 30 min, and then the supernatant was collected.

Mass spectrometry
ES-CID-MSn experiments were performed on a linear trapping quadrupole (LTQ) instrument
(ThermoFinnigan, San Jose, CA) equipped with a positive ion nanospray ionization source and New
Objective (Woburn, MA) nanospray silica tips. Samples were diluted in 50% aqueous methanol
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containing 0.1% formic acid, and infusion loaded into the LTQ at a flow rate of 1 µL/min. The instrument
was operated at a spray voltage of 2 kV and a capillary temperature of 180 °C. Tandem mass spectra were
acquired at a setting of 30% “normalized collision energy” of the precursor ions at m/z = 324.2, 392.3 and
394.3 corresponding to the three protonated prodiginines with an isolation width of 2.5 Da. Each MS and
MSn spectrum was acquired and averaged within 1 min.
All neutral loss (NL) scans, and also all mass spectra appearing in Supplementary Data, were performed
on an Applied Biosystems/MDS SCIEX (Foster City, CA) 3200 QTRAP hybrid quadrupole/linear ion trap
mass spectrometer with direct infusion of each prodiginine sample in aqueous methanol (50/50) spiked
with 0.1% formic acid at a flow rate of 4 µL/min. Positive ion mode ES-MS was used for the analysis,
with the Turbo VTM source settings for prodiginines optimized as follows: ionspray voltage 5.5 kV,
declustering potential 60 V, source temperature 120 °C, GS1 40 and curtain gas 10. Ultrahigh grade
(99.999%) nitrogen was utilized as nebulizing gas and collision gas. To maximize resolution of ionizable
species in the complex sample, MS spectra were acquired using Q3 in the linear ion trapping (LIT) mode.
For the activation energy comparison using the 3200 QTRAP mass spectrometer, single collision
conditions ensured well-controlled energy deposition on the target ions during the ion activation event
with parent beam transmission ≥ 90%. The ion abundances of the fragments from competing pathways
were monitored as the collision energy was ramped from 5 to 80 eV. Each data point shown in the
breakdown curve represents an average of five consecutive runs, and error bars (showing +/- standard
deviation) were calculated from the five experiments.

Computational methods
All computational calculations were performed using the Gaussian 03 (revision B.03) program.24 The
density functional B3PW91/6-31G* procedure (which combines the Becke three-parameter hybrid25 and
the Perdew-Wang correlation functionals26) was used to optimize geometries and these obtained
structures were then used to find energy minima at 0 K (B3PW91/6-311+G(2d,2p)) with zero-point
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correction. When calculating transition states, opt=QST2 and opt=QST3 features were used with the
relevant optimized reactants and products.

Results and Discussion
In positive ion electrospray mass spectra, the ions observed are generally “molecular ions” representing
intact forms of the analyte molecules; those created by proton attachment are denoted as [M+H]+. These
ions are even-electron (EE+) species that are generally much more stable than odd-electron ions (OE+⋅)
formed, for example, by electron ionization. Even-electron ions such as protonated molecules formed by
ES rarely decompose under low-energy collisions by homolytic cleavage involving loss of a radical to
form OE+⋅ + ˙n (radical neutral) because the barrier to this type of process is almost always higher than
those of competing processes. Rather, heterolytic bond cleavages, often involving rearrangement(s)
(especially proton transfer(s)) reign. Thus, radical losses from EE+ species are considered to be forbidden,
which is a statement of the “even-electron rule”.27 Certain exceptions to this “rule” have been reported
where odd-electron ions were formed through the fragmentation of even-electron ions formed during
electron ionization or chemical ionization or electrospray ionization28-32. These exceptions to the
“even-electron rule” were proposed to involve radical eliminations leading to odd-electron fragment ions
of exceptional stability.33
The goal of the current study is to obtain a comprehensive view of the common fragmentation pathways
of prodiginines, while mainly focusing on the odd-electron fragments observed in ES-tandem mass
spectra. Even though three investigated prodiginine analogs share a common skeleton (Scheme 1),
differences in the behavior of the protonated molecules following ion activation were seen due to the
varying alkyl chain substituents on the C-ring.

Interpretation of the Detailed Fragmentation Pathways of Prodigiosin
Although the collision induced dissociation (CID) mass spectra of some prodiginines have been
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reported,34 to our knowledge there has been no detailed description of mass spectra, nor interpretation of
their fragmentation mechanisms in the literature. In our CID mass spectra of three prodiginine analogs,
similarities in the fragmentation patterns were readily discernable. In each case, a stable OE+⋅ fragment
ion is initially formed through the loss of a 15 Da neutral, which we deduce can only be a methyl radical.
Methyl radical loss was also observed during the fragmentation of ES-generated protonated flavanones.31
Because this 15 Da loss is common to MS/MS spectra of all three prodiginines, we conclude that it must
correspond to loss of the methyl moiety of the methoxy group on the B-ring (m/z 324 Æ 309, m/z 394 Æ
379, m/z 392 Æ 377 in Figures 4.1, 4.2, and 4.3 respectively). Even though prodigiosin has another
methyl substituent in the C-ring, neither of the other two prodiginines have a second methyl group, hence,
C-ring methyl loss is eliminated as the source of 15 Da loss. The fully conjugated skeletons provide much
resonance stabilization for both the charge and the unpaired electron; when the latter is associated with
the C-ring it can initiate cleavages on the substituent alkyl chains. To aid in the interpretation of the
fragmentation mechanisms, CID-MS3 experiments were performed on the OE+⋅ ions of particular interest
(i.e., m/z 309, 379 and 377 in Figures 4.1, 4.2 and 4.3, respectively). From these latter ions, obtained MS3
spectra could readily rationalize consecutive cleavages that appeared in the MS2 spectra. For example, it
can be seen that alkyl chain cleavages yield the predominant fragment ions at m/z 238 and 252 observed
in the CID spectra of all three prodiginine analogs.
As a competing pathway, EE+ fragments are derived from the loss of methanol (m/z 324 Æ 292, m/z 394
Æ 362, m/z 392 Æ 360 in Figures 4.1, 4.2 and 4.3, respectively). The ion abundance of this EE+ product
is substantially lower than those of the OE+⋅ fragments (m/z 309, 379 and 377, respectively) observed in
the tandem mass spectra, but it is clear that the methoxy group is involved, carrying a proton in tow in
each case of methanol loss. Other OE+⋅ fragments were also observed in the CID spectra of prodigiosin
and its two analogs. Additional information to aid in elucidating the structure was gained using a third
stage of tandem mass spectrometry. The OE+⋅ products (m/z 324 Æ149 (Figure 4.1), m/z 392Æ 295
(Figure 4.3)) were further fragmented using on-resonance CID in the linear ion trap, giving major EE+
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Figure 4.1 ES-CID-MSn spectra for prodigiosin and the proposed major fragmentation pathways: (A)
MS/MS spectrum of [M+H]+ precursor at m/z 324; (B) MS3 spectrum of m/z 309 (324Æ309); (C) MS3
spectrum of m/z 149 (324Æ149)
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fragments (m/z 134 and 252, respectively) after CnH2n+1 radical (n = 1 and 3) elimination.

The detailed

mechanisms proposed for the fragmentations of the three investigated compounds are illustrated in
Figures 4.1- 3.
Additional evidence supporting these proposed mechanisms was obtained by repeating tandem mass
spectrometry

measurements,

except

that

this

time,

a

stable

isotope

labeled

[13C-methoxy-undecylprodiginine + H]+ m/z 395 precursor was used (see supplemental data). All product
ions appeared at exactly the same m/z values as those derived from the unlabeled [undecylprodiginine +
H]+ m/z 394 precursor. This unambiguously implicates the methoxy function in both methyl radical and
methanol losses, and establishes that all other product ions arise from consecutive decompositions
following one of these initial losses.

Computational Studies of the Fragmentation Pathways of Prodiginine
To investigate the underlying basis for the fragmentation pattern of protonated prodiginines, theoretical
calculations were employed to gain additional information concerning the competition between methyl
radical and methanol losses. Density functional theory (DFT) calculations were performed to obtain the
structures of the precursor ion and its decomposition products, transition states and their associated
energies. Due to the large numbers of atoms in the molecules of interest, it is time consuming to
computationally minimize the energies of the structures using DFT, especially when a long alkyl chain
with many approximately isoenergetic conformers is present. To reduce this difficulty, in all calculations,
we employed an ethyl analog of the undecylprodiginine system, i.e., C2H5 substitution on the C-ring
instead of C11H23. Traditionally, the structures of prodiginines have been drawn with the three nitrogen
atoms of the tripyrrole skeleton oriented on the same side of the molecule (Scheme 1). However,
theoretical calculations find that the A- and C-rings in Figure 4.1 are rotated about 180º such that the
molecules are still nearly planar, but nitrogen lone pairs are located as far apart as possible to minimize
the electronic repulsion, and hence, the system achieves the highest stability. Figure 4.4(a) I shows the
energy optimized geometry obtained at the B3PW91/6-31G* level of theory, 4(a) II shows the chemical
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structure, while 4(a) III shows the electron density map. Electron density mapping provides insight into
the electron distribution over the molecule and also allows prediction of the preferred site of proton
attachment on the molecule. As can be seen in Figure 4.4a (III), the lone pair of electrons of the nitrogen
atom in the B-ring exhibits the highest electron density, and thus, is clearly the preferred site of proton
attachment. In view of the fully conjugated structure, the positive charge carried by the ionizing proton
becomes highly delocalized over the entire ring system. In considering [M+H]+ ions observed in mass
spectra, and placing the ionizing proton on the nitrogen that previously holds no proton, the energies of
three stable conformers were calculated at the B3PW91/6-311+G(2d,2p) level of theory; the relative
stabilization energies are listed below each corresponding structure (Figure 4.4b). Very importantly, a
hydrogen bond may form between the C-ring proton attached to the nitrogen atom and the oxygen from
the methoxy function to produce a pseudo-seven-membered ring (Scheme 2) which represents the most
stable ground state conformation.
With the proton held (chelated) between the C-ring nitrogen and the methoxy oxygen (O···H distance =
1.397 Å), two facile decomposition pathways are possible. The first pathway is the expected loss of a
methanol molecule that, afterwards, according to energy minimization studies, undergoes ring closure to
form a new fused five-membered ring structure (Scheme 2). The second pathway is homolytic cleavage
between the oxygen and carbon atoms of the methoxy group to produce loss of ˙CH3 which was
experimentally observed to be surprisingly facile and favored.
Geometry optimization and vibrational frequency analysis for the reactant and the two products were
carried out at the B3PW91/6-31G* level. These structures were then used to perform single point energy
calculations at the B3PW91/6-311+G(2d,2p) level with zero-point energy correction. The calculated
relative energies of the two endothermic products are 121.6 (EE+ product) and 226.8 (OE+⋅ product)
kJ/mol (Scheme 2) rendering methyl loss more endothermic by 105.2 kJ/mol. Thus, the preference for
methyl radical loss over methanol loss cannot be explained by the energy difference between the reactant
and the respective products.
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Comparison of Aparent Tresholds and Ativation Eergies for the To Cmpeting Mechanisms
To obtain more insight into the competing processes of methyl radical loss vs methanol loss from
protonated prodiginine, a profiling of the fragment ion populations from each pathway as a function of
increasing energy under single collision conditions was undertaken in the low-energy regime. Figure 4.5A
presents the breakdown curve of the protonated prodigiosin precursor (m/z 324), plus the appearance of
the fragments associated with methyl radical loss (m/z 309 and 252) and methanol loss (m/z 292). Most
notably, methyl radical loss has the lowest apparent threshold (Elab ≈ 5 eV) and its consecutive
fragmentation pathway (giving m/z 252, Figure 4.1) appears instantaneously thereafter.
Methanol loss exhibits a higher apparent threshold (Elab ≈ 12.5 eV) compared to the former loss.
Surprisingly, Figure 4.5A shows that, regardless of collision energy, the abundances of m/z 309 and 252
are always more than 10 times higher than that of m/z 292. MS/MS spectra that were acquired at collision
energies of 5 and 12.5 eV (Elab) are shown in Figure 4.5B.
Methyl radical loss thus has a lower apparent threshold, but it is also a more endothermic pathway than
methanol loss. This implies that OE+⋅ production is favored because methyl radical loss presents the
lowest available kinetic barrier. Computational studies were used in an attempt to calculate activation
energies, and a transition state structure for loss of methanol from protonated prodiginine with only one
imaginary frequency was successfully obtained. The activation energy for loss of methanol from
protonated prodiginine was calculated to pass through a transition state that was found to be 373.3 kJ/mol
higher in energy than the ground state reactant. Unfortunately, our attempt to obtain a transition state for
methyl radical loss from protonated prodiginine was unsuccessful, but nonetheless, the experimental data
in Figure 4.5 proves that the energy barrier for this latter process is significantly lower than that of
methanol loss.
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Figure 4.4 (a) Structures of neutral prodiginine model system showing the preferred site for the proton
attachment during electrospray ionization process. (I) the energetically optimized geometry at the
B3PW91/6-31G* level; (II) chemical structure; (III) electron density map (sequence of electron density
listed as followings: purple > blue > green > yellow > red) indicating highest electron density at the
central nitrogen bearing no proton. (b) The optimized prodiginine conformations and the relative energies
calculated by density function theory (DFT).
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Scheme 4.2 Two competing fragmentation pathways of the protonated prodiginine model system leading
either to OE+˙ after homolytic cleavage to lose a methyl radical, or to EE+ after heterolytic bond
dissociation to lose a methanol molecule.
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New Strategy for Prodiginine Identification
Because of the distinct and unusual nature of the fragments resulting from the competing losses of either
methyl radical or methanol, we decided to make an attempt to analytically exploit this uniqueness, and
use the combination of the two losses as a characteristic marker for prodiginine-type compounds. The
instrument design of the QTRAP mass spectrometer enables neutral loss (or gain) scans of all ions
generated in the ion source, thus enabling a quick screening of all the analytes present in a crude mixture
that undergo a specific type of decomposition. Neutral loss scans of 15 Da (representing a methyl radical)
and 32 Da (representing a methanol molecule) were performed using the crude sample extract from H.
chejuensis in which prodigiosin was previously identified using preparative LC separation and NMR
spectroscopy34. The 15 Da neutral loss scan detected not only prodigiosin, but also a new, low abundance
prodigiosin analog from the crude mixture (no purification step). A subsequent 32 Da neutral loss scan
confirmed the presence of this prodigiosin analog. These results are summarized schematically in Figure
4.6. The ES mass spectrum (Figure 4.6A) reveals protonated prodigiosin as the base peak at m/z 324.
Figures 4.6B and 4.6C show the neutral loss mass spectra corresponding to methyl radical and methanol
losses, respectively, in which both prodigiosin (m/z 324) and its analog (m/z 352) appeared.
The characterization of the analog at m/z 352 is based on its tandem mass spectra (Figures 4.6D and 4.6E).
Like the other prodiginines, it shows fragments resulting from various alkyl chain cleavages. The
pathways leading to the observed fragments are proposed at the bottom of Figure 4.6. In the
fragmentation mechanism of prodigiosin (Figure 4.1), we proposed that the product ion at m/z 252 was
generated from cleavage of the alkyl chain on the C-ring. The proposed pathway to form the same
fragment at m/z 252 (in Figures 4.6D and 4.6E) indicates that the analog shares the same backbone as
prodigiosin (including the methyl group on the C-ring) but differs in the nature of the second alkyl chain.
The presence of a (second) methyl loss (in Figure 4.6E) leading to m/z 322 further supports the notion
that, similar to prodigiosin, a second methyl group exists on the C-ring. Thus, the evidence suggests that
the mass difference of 28 Da between the two compounds reflects the extension of the longer alkyl chain
on the C-ring of prodigiosin by two -CH2- units. Additional evidence is provided by the fragment ion at
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Figure 4.5 (A) Breakdown curves showing ion abundance vs. collision energy for MS/MS of
prodigiosin. The plots show the evolution of precursor and fragment ions representing two competing
pathways (m/z 324 = precursor; m/z 309 and 252 represent the formation of OE+⋅ by methyl radical loss
and methyl radical loss plus consecutive butyl radical loss, respectively; m/z 292 represents the formation
of EE+ after the loss of methanol) (B) The MS/MS spectra of the m/z 324 prodigiosin precursor with
collision energies of 5, 10 and 12.5 eV performed under single collision conditions
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m/z 177 derived from the precursor at m/z 337 (Figure 4.6E) that was generated from the same pathway
as the fragment at m/z 149 in the tandem mass spectrum of prodigiosin (Figure 4.1). This mass difference
of 28 Da between these two fragments confirms the extension of the alkyl chain substitution on the C-ring.
However, one cannot determine by mass spectrometry alone whether the alkyl chain is branched or not.
Thus, we identified the analog as containing a C7H15 saturated alkyl chain on the C-ring instead of C5H11
in prodigiosin.34 Because prodigiosin and undecylprodiginine both contain n-alkyl chains, we assign the
new analog as also being unbranched.
The studies described herein have thus proven that our approach of using a combination of constant
neutral loss scans (15 Da and 32 Da) is selective for the detection of unknown and low abundance
prodiginine compounds; the strategy is built upon the ease of loss of methyl radicals from their common
backbone structure. Without labor-intensive purification steps, the workload for identification and
characterization of prodiginines can thus dramatically decrease using our approach. Owing to the
excellent sensitivity of mass spectrometry, the sample quantity requirements could also decrease from
milligrams (for NMR) to less than micrograms (for mass spectrometry) of a crude mixture.
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Figure 4.6 (A) Positive ion ES-MS spectrum of the extract from H. chejuensis showing [M+H]+ of m/z
324 from prodigiosin, and m/z 352 from the analog; (B) positive ion neutral loss (15 Da) spectrum,
showing both prodigiosin and its analog at m/z 324 and 352, respectively; (C) positive ion neutral loss
spectrum of 32 Da mass loss, showing both prodigiosin and its analog at m/z 324 and 352; (D) Positive
ion ES-MS/MS spectrum of protonated prodigiosin analog at m/z 352; and (E) MS3 spectrum of m/z 337;
the proposed fragmentation pathways of protonated prodigiosin analog at m/z 352
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Conclusion
The fragmentation behavior in positive mode electrospray mass spectrometry of three representative
members of prodiginines which share the same pyrrolydipyrrolylmethene skeleton has been investigated.
Two competing fragmentation pathways were the loss of either methyl radical or methanol and, in
violation of the even electron rule, the CID spectra were dominated by the former pathway to yield OE+⋅
products which may undergo consecutive fragmentations. Upon structural optimization of reactant MH+
precursors using a Gaussian 03 computational program, results indicate that the nitrogen atom at the
C-ring and the B-ring methoxy function could effectively chelate a proton to form a relatively stable
H-bonded pseudo-seven-membered ring. From this precursor, methyl radical loss is the most facile
decomposition pathway as evidenced by its dominance in low-energy tandem mass spectra. In a
competitive pathway, the loss of a methanol molecule involving the same methoxy site on the precursor to
produce an EE+ fragment was heavily disfavored. The apparent threshold of the former pathway has been
shown to be much lower than the latter by profiling the ion population of the major fragments of
protonated prodigiosin against collision energy under single collision conditions. Thus, the fragmentation
of prodiginines was kinetically dominated by methyl loss over methanol loss as a first step. Moreover, the
characteristic and unusual loss of methyl radical from each prodiginine, in favorable competition with
methanol loss, is useful for rapid identification and structural elucidation of novel prodiginines by
performing constant neutral loss scans (˙CH3, 15 Da and CH3OH, 32 Da) to identify all prodiginines
present in a mixture.
Using analytical methodology built on this strategy, we report a new and low abundance prodigiosin
analog from H. chejuensis. Because methyl radical loss rarely occurs in the fragmentation of most
ES-generated compounds (EE+ species), the selectivity of the method will permit high sensitivity
identifications of prodiginines from crude extracts of different bacterial species.
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Chapter 5

Hypoxia-Induced Changes in the Zebrafish Skeletal Muscle Proteome
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Abstract
Oxygen deficiency occurs under many pathological, physiological, and environmental conditions. To
identify changes in protein expression patterns induced by hypoxic exposure, a quantitative proteomics
technique (2D-DIGE: two-dimensional difference in-gel electrophoresis) was used to compare the
zebrafish skeletal muscle protein profile in vivo after 48 h in hypoxia (PO2 = 1.9 kPa) or normoxia (PO2 =
18.6 kPa). Proteins were separated over two pH ranges in the first dimension (pH 4-7 and pH 7-11), prior
to separation in the second dimension, resolving over 1000 total protein spots. Of these, 34 spots in the
pH range of 4-7 and 15 in the pH 7-11 range showed statistically significant differences between the
hypoxic and the normoxic groups. Twenty-three spots in the pH 4-7 range and 8 in the pH 7-11 range
were identified using MALDI-TOF/TOF mass spectrometry. Spots identified as glycolytic enzymes were
higher during hypoxia than in normoxia, whereas enzymes associated with mitochondrial ATP synthesis
were lower during hypoxia. Interestingly, hypoxic samples exhibited higher expression of proteins
identified as zebrafish hemoglobin α variants. These protein expression changes are consistent with a
hypoxic response that enhances anaerobic metabolism or O2 transport to tissues.
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Introduction
Hypoxia (reduced availability of oxygen) occurs under a variety of physiological, pathological, and
environmental conditions. Mountain sickness is an outcome of people unaccustomed to high altitude who
experience insufficient oxygen delivery to body tissues due to decreased oxygen partial pressure at high
elevation.1,

2

In cancer, experimental and clinical studies show that hypoxia is the consequence of

functional and structural disturbances in microcirculation, and tumor hypoxia has become a central issue
in cancer treatment owing to its postulated linkage with tumor progression and resistance to therapies.3-5
Aquatic hypoxia occurs naturally in many areas; however, the number and size of impacted areas and the
duration of hypoxic episodes have all been increasing as a consequence of human activities.6 For example,
the growing hypoxic zone of the northern Gulf of Mexico has reduced the size of the suitable habitat for
pelagic species and caused death of bottom-dwelling species that cannot move out of the hypoxic area.7
Many species cope with oxygen deficiency by regulating activities at the systemic, cellular and molecular
levels to ameliorate the negative effects of hypoxia. Among mammals, numerous studies demonstrate that
the transcription factor, hypoxia inducible factor-1 (HIF-1)8-10, plays a central role in regulating the
molecular response to low oxygen. This transcription factor consists of a constitutively expressed β
subunit and an oxygen-regulated α subunit. The latter contains an oxygen-dependent degradation domain
recognized by the Von-Hippel-Lindau protein (pVHL). Under conditions of oxygen sufficiency, pVHL
binds HIF-1 α and directs the protein to degradation by the ubiquitin-proteasome pathway. Under hypoxia,
degradation is blocked, HIF-1 α accumulates and dimerized with HIF-β, and the dimer binds regulatory
regions of target genes. In this fashion, HIF-1 regulates the expression of genes involved in enhancing
oxygen delivery,11 glucose uptake, and glucose metabolism.12
Fish are the oldest and most diverse group of vertebrate animals. Bony fish comprise nearly one-half of
the known species of extant vertebrates and they are found in virtually every aquatic habitat.13 The
phylogenetic and ecological diversity of fish offers distinct advantages in studies of environmental
adaptation, such as the adaptive response to hypoxia.14 Zebrafish (Danio rerio) is a well-characterized
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species used to study development15, 16, and to a lesser extent, adult physiology. Previously, cDNA
microarray studies showed large-scale changes in mRNA levels in zebrafish embryos17 and adults18
exposed to low oxygen. The response to hypoxia includes changes in the expression of genes involved in
glycolysis, oxidative metabolism, and protein synthesis. At the proteome level, however, Bosworth et al.19
showed more subtle effects, with a small number of low abundance proteins changing in skeletal muscle
during hypoxic exposure of adult zebrafish. Those proteins were not identified due to their low amounts
in two-dimensional polyacrylamide gel electrophoresis (2D-PAGE).
The development of two-dimensional difference in gel electrophoresis (2D-DIGE) improves
conventional 2D-PAGE by minimizing gel-to-gel variation and broadening the linear dynamic range for
protein quantification.20 The use of size-matched, spectrally-distinct cyanine dyes (CyDyes) allows
detection and quantification of differentially expressed proteins within a single gel. Current MALDI-TOF
mass spectrometry technology provides low femtomole level detection limits and less than 10 ppm error
in mass accuracy that are critical for protein identification. Thus, 2D-DIGE followed by MALDI
TOF/TOF analysis allows reproducible protein expression profiling and identification in a high
throughput manner. In the current study, 2D-DIGE and MALDI TOF/TOF were used to explore the
proteomic response to hypoxia in the zebrafish skeletal muscle proteome.

Experimental
Chemicals and Reagents
C18 ZipTips for desalting and purifying tryptic peptides were purchased from Millipore (Bedford, MA).
The 4700 Calibration Standard kit used in calibrating MS or MS/MS spectra was purchased from Applied
Biosystems Inc., Foster City, CA. CyDyes, Immobiline DryStrip 24 cm gels, carrier ampholytes of
different pH ranges and other reagents for the first dimension of electrophoresis were purchased from GE
Healthcare (Piscataway, NJ). Second dimensional electrophoresis employed Nextgen Sciences precast
8-16% gradient gels (Ann Arbor, MI). The Zoom® IEF Fractionator and reagents were purchased from
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Invitrogen (Carlsbad, CA). All other chemicals and reagents not listed here were either analytical or
electrophoresis grade, and they were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO).
Animals
Wild-type zebrafish of both sexes were purchased from a local pet store, randomly divided into two
groups of 10 fish, and held in two 40 L aquaria. Prior to experimentation, zebrafish were acclimated for
four weeks in well-aerated, dechlorinated tap water at room temperature (19 ± 0.3 °C). Fish were fed
twice a day throughout the acclimation period. At the start of hypoxic exposure, the water in one
aquarium was made hypoxic (PO2 = 1.9 kPa) over 2 h by gassing with a mixture of 0.9 L/min nitrogen and
0.1 L/min air. Gassing was continued for 48 h, a length of exposure that adult zebrafish tolerate with
minimal mortality.21 The control tank was maintained at nomoxia (PO2 = 18.6 kPa) by gassing with room
air at approximately the same flow rate. Both aquaria were covered and fish were not fed throughout the
exposure period. At 48 h, fish were rapidly netted and frozen in liquid nitrogen. Fish were kept at -80 °C
until analyzed.

Preparation of Protein Extracts
White skeletal muscle was dissected while fish were maintained frozen, taking care to exclude red
skeletal muscle and skin. Approximately 100 mg of tissue was pulverized under liquid nitrogen, and then
homogenized using a glass-glass homogenizer in 1 mL sample buffer (SB; 7 M urea, 2M thiourea, 2%
CHAPS, 1% ASB-14) with 40 mM DTT. The protein extracts were centrifuged at 30,000×g for 30 min at
8 °C. The remaining insoluble pellet was discarded, and the soluble muscle protein extracts were stored at
-80 °C. The protein concentration of the resulting supernatant was measured with a GE Healthcare 2D
Quant kit (Piscataway, NJ).

Two-dimensional Polyacrylamide Gel Electrophoresis
Samples were desalted with a GE Healthcare 2D cleanup kit (Piscataway, NJ) and re-dissolved in SB (see
above) plus 15 mM Tris buffer at pH 8.5. Samples of 50 µg of protein from each fish were reacted with
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200 pmol of either Cy 3 or Cy 5 in a final volume of 10 µL on ice for 30 min in the dark. Labeling
reactions were stopped by adding 1 µL of 10 mM lysine. To control for potential bias in labeling
efficiency of CyDyes, half of the extracts from each experimental group were labeled with Cy 3 and the
other half labeled with Cy 5 (Figure 5.1). A pooled protein sample was made by combining equal amounts
of protein from all the individual replicates. This pooled sample was labeled with Cy 2 and used to
normalize protein abundances across different gels, thereby allowing a correction for gel-to-gel variations.
Labeled samples were kept at -80 °C until use.
For DIGE analysis, each gel contained 50 µg of one hypoxic extract labeled with either Cy3 or Cy 5, plus
50 µg of one normoxic extract labeled with the alternative CyDye (Cy5 or Cy3, respectively), and 50 µg
of the Cy 2 labeled pooled protein sample. Mixed samples were cup-loaded on 24 cm rehydrated IPG
strips, covering a pH range of either 4-7 or 7-11. For pH 4-7, non linear pH gradient IPG strips were
rehydrated in sample buffer plus 20 mM DTT. For pH 7-11, IPG strips, were rehydrated in the SB
containing 1.2% “destreak” reagent (GE Healthcare). Protein samples were then focused on the Ettan
IPGphor IEF apparatus until 60,000 Vhr.
After the IEF separation, IPG strips were equilibrated in 50 mM Tris-HCl, pH 8.8, 6M Urea, 30%
glycerol, 2% SDS containing 1% DTT for 15 min to reduce disulfide bonds. Strips were then alkylated in
the same buffer with 2.5% iodoacetamide in place of DTT for another 15 min. The equilibrated strips
were loaded onto Nextgen Sciences 8-16% SDS-PAGE (25 cm × 20 cm) gradient gels in a GE Healthcare
EttanTM DALTsix system (Piscataway, NJ) and run at the constant power of 15 W and the temperature of
25 °C until the bromophenol blue tracking dye migrated to the bottom of the gel (4.5 - 6 h).

Protein Visualization and 2D-DIGE Gel Image Analysis
Images of gels were acquired with a GE Healthcare Typhoon 9400 Laser Scanner (Piscataway, NJ) using
filters specific for each CyDye. Nonlinear Dynamics Progensis Samespots software was used for image
alignment, spot detection, and spot quantification. Cy 2 images were used to match the gels. Spot
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Figure 5.1 Experimental design of 2D-DIGE, preparative gel electrophoresis, and identification of
zebrafish skeletal muscle proteins.
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volumes for each spot in hypoxic and normoxic extracts were normalized to the Cy 2 volume for the same
spot in the same gel. Analysis of variance was used to determine whether a significant difference existed
between normalized spot volume of hypoxia and normoxia samples. Spots that differed significantly
(ANOVA P < 0.05) were visually examined to determine whether they were of good quality and present
in the entire image set.

Preparative 2D-PAGE and in-gel Digestion
To identify the spots of protein whose expression changed during hypoxia, two separate preparative gels
were run at pH 4-7 and 7-11 intervals. In the pH 4-7 range, 600 µg of the pooled protein sample was
subjected to 2D-PAGE and the resulting gel was stained with colloid coomassie blue. To enrich proteins
in the pH 7-10 range, samples were first subjected to in-solution IEF using the Invitrogen Zoom® IEF
Fractionator (Carlsbad, CA) run at 100 V for 20 min, 200 V for 80 min and 600 V for another 80 min. The
fraction between pH 7 and 10 was retrieved from the electrophoresis chamber and precipitated using a 2D
Cleanup kit. After protein assay, 200 µg protein was redissolved in 100 µL of the SB containing 15 mM
DTT and used for 2D-PAGE as described above (pH 7-11NL IPG strip). These high pH preparative gels
were stained with BioRad Flamingo fluorescent dye (Hercules, CA). Spots of interest from DIGE analysis
were mapped onto images of the preparative gels and excised with a Biorad EXQuestTM spot cutter
(Hercules, CA). Gel pieces were collected in 96-well plates and digested with trypsin using a Genomic
Solutions ProGestTM (Ann Arbor, MI).

Mass Spectrometry
The tryptic digests were purified using C18 Ziptips (Millipore) and eluted in 4 µL of 50:50
acetonitrile:H2O containing 0.1% TFA. Aliquots of 0.5 µL were dispensed on the sample support,
followed by the addition of an equal volume of 10 mg/mL α-cyano-4-hydroxycinnamic acid in 50:50
acetonitrile:H2O containing 0.1% TFA. MS and MS/MS spectra were acquired using Applied Biosystem
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4800 MALDI-TOF/TOF mass spectrometer (Foster City, CA) in the positive reflectron mode. Two
trypsin autolysis peaks at m/z 842 and 2211 were used as internal standards for MS calibration. Peptide
mass fingerprints were acquired using 600 laser shots in a mass range between m/z 800 and 4000. The ten
most intense peptide precursors were selected for MS/MS product ion acquisitions to confirm protein
identifications, and the MS/MS spectra were acquired using 2500 laser shots. Data were transferred to
GPS explorer software and searched against the zebrafish subset of the NCBInr database and the
zebrafish subset of the IPI FASTA sequence database with parameters: enzyme = trypsin; fixed
modification = carbamidomethyl; variable modification = oxidiation of methione; max missed cleavages
= 1; precursor tolerance = 100 ppm; and MS/MS fragment tolerance = 0.5 Da. Where spots were
identified as unknown proteins, homology to known proteins was determined using BLAST22.

Results
Optimization of 2D-PAGE separation
2D-PAGE enables visualization and quantification of hundreds of proteins including post-translationally
modified forms and related isoforms. However, great care must be taken to optimize 2D-PAGE separation
conditions, which depend on sample type. For skeletal muscle, abundant proteins including actin, myosin,
and tropomyosin, frequently compromise the separation and quantification of low abundance proteins on
2D-PAGE. In preliminary experiments, different forms of protein loading (active or passive rehydration,
cup loading), different types and concentrations of detergents (1-4% CHAPS, 0.4-1% ASB-14), and first
dimension IEF running conditions (30-80 kVhrs) were tested to achieve the best separation of zebrafish
skeletal muscle proteins. The final conditions are given in the experimental section.

2D-DIGE Analysis
Of ten fish in the normoxic or hypoxic groups, nine were randomly selected for 2D-DIGE analysis. After
removing gels with either severe horizontal streaking or low CyDye labeling efficiency, eight independent
gels in the pH 4-7 range and seven gels in the pH 7-11 range were used to compare the zebrafish skeletal
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muscle proteome between hypoxia and normoxia. These gels showed that the general pattern of zebrafish
skeletal muscle protein expression under hypoxia was very similar to that under normoxia (Figure 5.2).
DIGE analysis revealed that, across the entire pH range assayed (4 to 11), only 49 of 1100 spots (~ 4.4%;
around 700 spots in the pH 4-7 range and 400 spots in the pH 7-11 range) showed significantly different
levels of expression. Thirty-four spots in the pH range of 4-7 and 15 spots in the pH range of 7-11 showed
statistically significant differences in quantity between the hypoxic and the normoxic groups (ANOVA P
< 0.05). In the pH 4 to 7 range, 26 spots were more abundant in the hypoxic group and 8 spots were less
abundant in the hypoxic group; in the pH 7-11 range, 7 spots were more abundant under hypoxia while 8
spots were less abundant.

Protein Identification
Protein spots found to be up-regulated or down-regulated during hypoxia were excised from preparative
gels, digested, and subjected to MALDI-TOF/TOF mass spectrometry. Twenty three spots in the pH 4-7
range and 8 spots in the pH 7-11 range were successfully identified (see Appendix). Successful
identifications were defined as those peptides achieving MASCOT scores higher than 53 (P < 0.05). From
MS/MS experiments where fragment ions were successfully matched, MASCOT scores included these
peptide ion scores. Protein identifications were performed by searching the MS data against the zebrafish
subset from either NCBInr or the IPI FASTA sequence database. Searches against the ray-finned fish
subset of NCBInr database yielded similar results.
Two spots in the pH range of 7-11 having molecular weights near 16kDa were determined as hemoglobin
α variants (spot no. 0904 and 0909; Table 5.1). As shown in Figure 5.3, the expressions of both the spots
are higher in the hypoxic fish than in the normoxic fish. One-way ANOVA showed that changes in protein
expressions are highly statistically significant (P < 0.002; Table 5.1). Additionally, matches of peptide
masses and fragment ions from MS/MS to variants of Hb α (Accession Nos. CAE48980 and CAE48986)
were extremely significant (both P ~ 10-29). Figure 5.4 shows the amino acid sequences of the two
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Figure 5.2 The Cy 2 images of representative 2D-DIGE gels between pH 4-7 (A) and 7-11(B) intervals.
Proteins from the hypoxic or normoxic samples were labeled with either Cy 3 or Cy 5 dye. A pooled
internal standard combining all extracts, labeled with Cy 2 dye, was included in all gels. Spots that
differed between hypoxia and normoxia are indicated with spot number. These spots were selected for
mass spectrometric analysis.
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matched polypeptides with the peptides identified by MALDI-TOF/TOF shown in bold. Sequence
coverage of both polypeptides was around 50%. Below these two polypeptides are other zebrafish globin
protein sequences: hemoglogin α adult-1 (Hb α); hemoglobin β (Hb β), myoglobin (Mb), cytoglobin
(Cygb), neuroglobin (Nb) and globin X (gbX). Spot 0909 (CAE48986) differs from adult zebrafish Hb α
adult-1 by one amino acid, whereas spot 0904 (CAE48980) differs by only two amino acids (highlighted
residues). In contrast, the sequences of all Hb α variants are quite dissimilar to amino acid sequences of
other zebrafish globins and the peptides determined by MALDI-TOF/TOF are not found in other globin
genes. The results clearly demonstrate that spots 0904 and 0909, both up-regulated by hypoxic exposure,
are variants of Hb α.
Table 5.2 shows protein spots whose molecular weight in 2D-PAGE was considerably less than predicted
from their amino acid sequence. These spots likely represent fragments of the corresponding proteins.
Nine spots were up-regulated while three spots were down-regulated in the pH 4-7 range; one spot was
more abundant in the hypoxic group whereas one spot was less abundant in the hypoxic group in the pH
7-11 range. Most of these spots found to be more abundant during hypoxia were identified as highly
expressed proteins, myosin and creatine kinase. Four other spots, less abundant in the hypoxic group,
were determined as actin, mitochondrial ATP synthase, glycogen phosphorylase and isocitrate
dehydrogenase. Another up-regulated spot was identified as protein arginine N-methyltransferase.
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Table 5.1 Identification of differentially expressed spots corresponding to putative intact proteins
Spot
No.

Expression
Ratioa

ANOVA
P

1406
1181
1183
0809
0851
1244
0231
0923
1006

2.6
2.5
2.4
1.9
1.9
1.8
1.7
-1.3
-1.6

2.30E-03
1.39E-03
1.69E-03
1.07E-03
5.22E-03
9.69E-03
1.25E-02
7.70E-03
6.09E-04

0418

-1.8

7.47E-03

0713
0909

3.7
2.5

2.36E-02
1.81E-03

0904

2.3

2.24E-04

0586
0699

2.3
-1.4

2.09E-03
7.70E-03

0747

-2.5

4.00E-03

Mascot
Scoreb
pH 4-7
nucleoside diphosphate kinase-Z2
386
triosephosphate isomerase B
200
triosephosphate isomerase B
153
Enolase 1, (alpha)
372
pyruvate kinase, muscle, b [zgc:92037]
910
fast skeletal myosin light chain 1a
363
fast muscle-specific myosin heavy chain
143
Actin, alpha1, skeletal muscle
595
Pyruvate dehydrogenase (lipoamide)
211
beta
phosphorylase, glycogen; brain
152
pH 7-11
phosphoglycerate mutase 2 (muscle)
561
novel protein similar to zebrafish
194
hemoglobin alpha-adult 1 (hbaa1)
novel protein similar to zebrafish
326
hemoglobin alpha-adult 1 (hbaa1)
aldolase A fructose-bisphosphate,
384
hydroxyacyl-Coenzyme A
160
dehydrogenase
ATP synthase, H+ transporting,
149
mitochondrial F0 complex, subunit b,
isoform 1
Protein

Accession
Number

Coverage
(%)

Matched
Peptidesc

Mr (kDa)
obs/pred

pI
obs/pred

NP_571002
AAK85202
AAK85202
AAH59511
NP_001003488
NP_956294
AAK73348
NP_571666
AAH53233

59
53
39
46
58
73
17
49
43

9 (5)
10 (2)
7 (2)
14 (6)
31 (8)
17 (5)
15 (3)
15 (7)
13 (4)

16/17.2
28/27.1
28/27.1
50/47.4
53/58.8
28/21.0
95/95.0
42/42.2
39/39.7

5.0/6.75
6.2/6.45
6.5/6.45
6.5/6.16
5.9/6.88
5.5/4.63
6.1/5.22
5.0/5.23
5.1/5.78

NP_997974

10

9 (3)

95/97.7

6.7/6.11

NP_957318
CAE48986

63
53

18 (6)
6 (2)

30/29.0
15/15.5

9.0/8.83
8.0/7.98

CAE48980

47

6 (4)

15/15.5

9.0/8.88

NP_998380
NP_001003515

50
35

17 (4)
9 (3)

40/40.2
32/33.4

9.0/8.45
9.5/8.66

AAH83308

16

6 (2)

28/28.3

9.6/9.19

a. Positive expression ratios represent the ratio of the average normalized spot volume of the hypoxic to the normoxic samples (Vh/Vn). Negative
values correspond to spots more abundant in normoxic samples and calculated as – Vn/Vh.
b. Mascot scores over 53 are considered to be statistically significant (P < 0.05)
c. The number of peptides matched by PMF followed by the number of peptides with significant ion score
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Figure 5.3 2D-DIGE gel Images showing spots identified as zebrafish hemoglobin variants (spots 0904 (A) and 0909 (B)) with quantitative
comparison between hypoxia and normoxia shown below. The error bars represent the one standard deviation for n = 7 fish.
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Figure 5.4 CLUSTAL 2.0.8 multiple sequence alignment of the two identified hemoglobin variants (CAE48980 and CAE48986), with hemoglobin α adult-1
(NP_571332), hemoglobin β (NP_571095), cytoglobin (NP_694484), myoglobin (NP_956880), neuroglobin (NP_571928) and globin X (NP_001012261).
All sequences are from zebrafish (Danio reio). The peptides identified by mass spectrometry are shown in bold type. The highlighted residues (in yellow)
indicate the amino acid differences among the three Hb α sequences.
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Table 5.2 Identification of differentially expressed spots corresponding to putative protein fragments
Spot
No.

Expression
Ratioa

ANOVA
P

1089
1130
1077
0611
0571

2.7
2.6
2.4
2.2
2

8.75E-03
2.76E-03
6.11E-03
3.98E-03
2.52E-03

0367
0553
0349

2
1.8
1.6

4.00E-03
5.25E-03
5.10E-03

1221
0618
1188
1322
0775

1.5
1.4
-1.5
-1.6
-2

1.35E-02
6.51E-03
2.60E-02
1.18E-3
1.83E-02

0890
0682

2.3
-1.7

6.35E-03
1.32E-02

Protein

Mascot
Scoreb
pH 4-7
649
634
257
491
180

creatine kinase, muscle
creatine kinase, muscle
creatine kinase, muscle
myosin heavy chain 4 [Wu:fi38g05]
myosin binding protein C, fast-type
[Zgc:110761]
myosin heavy chain 4 [Wu:fi38g05]
58
myosin heavy chain 4 [Wu:fi38g05]
53
myosin, heavy polypeptide 2, fast muscle
68
specific
protein arginine N-methyltransferase 1
54
fast muscle-specific myosin heavy chain
752
actin, alpha 1, skeletal muscle
438
mitochondrial ATP synthase
293
phosphorylase, glycogen (muscle) b
76
[MGC63642]
pH 7-11
creatine kinase, muscle
351
isocitrate dehydrogenase 2 (NADP+),
372
mitochondrial

Accession
Number

Coverage
(%)

Matched
Peptidesc

Mr (kDa)
obs/pred

pI
obs/pred

NP_571007
NP_571007
NP_571007
AAH44194
AAH91662

32
48
18
19
11

13 (8)
18 (8)
7 (2)
20 (8)
14 (4)

35/43.0
35/43.0
35/43.0
80/125.2
80/125.8

6.6/6.32
6.6/6.32
6.5/6.32
6.0/6.21
6.5/5.56

AAH44194
AAH44194
NP_694514

6
9
7

8 (2)
11 (1)
14 (2)

96/125.2
80/125.2
96/222.8

6.0/6.21
6.6/6.21
6.1/5.55

NP_956944
AAK73348
NP_571666
AAS49605
NP_956766

29
34
26
26
13

10 (0)
32 (8)
7 (5)
9 (4)
5 (1)

30/40.0
80/95.0
30/42.3
20/40.0
70/36.9

5.9/5.47
5.0/5.22
4.8/5.23
5.8/9.18
6.5/6.27

NP_571007
NP_955858

32
27

14 (4)
12 (4)

30/42.3
20/40.0

4.8/5.23
5.8/9.18

a. Positive expression ratios represent the ratio of the average normalized spot volume of the hypoxic to the normoxic samples (Vh/Vn). Negative values
correspond to spots more abundant in normoxic samples and calculated as – Vn/Vh.
b. Mascot scores over 53 are considered to be statistically significant (P < 0.05)
c. The number of peptides matched by PMF followed by the number of peptides with significant ion score
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Discussion
While the overall pattern of protein expression was similar between hypoxia and normoxia, 2D-DIGE
analysis revealed that approximately 4% of the detected protein spots had statistically significant
differences in expression between the hypoxic and the normoxic zebrafish. Among the proteins that were
found to be up-regulated during hypoxia (Table 5.1), several were glycolytic enzymes, including
phosphoglycerate mutase 2 (3.7-fold), triosephophate isomerase B (2.4- and 2.5-fold), aldolase A
fructose-biphosphate (2.3-fold), enolase-1 α (1.9-fold) and pyruvate kinase (1.9-fold). Conversely,
down-regulated proteins included the enzymes of the citric acid cycle and proteins involved in aerobic
ATP production, such as pyruvate dehydrogenase (lipoamide) β (1.6-fold), hydroxyacyl-coenzyme A
dehydrogenase (1.4-fold), mitochondrial isocitrate dehydrogenase 2 (NADP+) (1.7-fold), mitochondrial
ATP synthase α (1.6-fold ) and ATP synthase (H+ transporting, mitochrondrial F0 complex, subunit b,
isoform 1) (2.5-fold) (Tables 5.1 and 5.2). The observation of up-regulated glycolytic enzymes and
down-regulated mitochondrial enzymes is entirely consistent with measurements of metabolic enzyme
activities23 and gene expression.17, 18 These patterns support the view of increased capacity for glycolysis
coupled with decreased capacity for aerobic ATP production during hypoxic exposure of fish.
Somewhat surprisingly, the results showed that a spot (spot no. 0418) identified as glycogen
phosphorylase was down-regulated by a factor of 1.8-fold after 48 h hypoxic exposure (Table 5.1).
Although database searching matched this spot against glycogen phosphorylase from brain, a hypothetical
protein corresponding to muscle glycogen phosphorylase matched almost as well (NP_956766; Mascot
score = 122). Glycogen phosphorylase catalyzes phosphorolytic cleavage of glycogen, releasing
glucose-1-phosphate. Its activity is regulated by reversible phosphorylation/dephosphorylation to generate
a more active a isoform or a less active b isoform. Intact zebrafish muscle glycogen phosphorylase has a
predicted Mr of 97 kDa and a pI of 6.7 in the unphosphorylated form, which compares quite well with the
pI and Mr of spot 0418 estimated by 2D-PAGE (6.7/95kDa; Figure 5.2A; Appendix Table A-1). Therefore,
this spot could be the unphosphorylated less active b form of the glycogen phosphorylase, and its increase
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suggests a reduced capacity for glycogen degradation during hypoxia. A spot corresponding to the
phosphorylated more active a isoform, however, was not detected as being up-regulated. Therefore, the
present 2D-PAGE data do not resolve whether glycogen phosphorylase phosphorylation status, and hence
enzyme activity, is altered by hypoxic exposure.
Data from cDNA microarray studies suggest that expression of genes encoding major contractile proteins
are down-regulation during hypoxic exposure of zebrafish.17 Consistent with that observation, the current
results indicate that protein spots corresponding to intact and fragmented actin were also down-regulated
by a factor of 1.3 and 1.5 fold, respectively, in skeletal muscle tissue after hypoxic exposure. Suppression
of high abundance cell structural proteins indicates that this may be an energy-saving strategy for hypoxic
zebrafish.17 However, some fragments of myosin respond differently to hypoxia. As shown in Table 5.1,
two spots determined as fast skeletal muscle myosin light chain 1a and fast muscle-specific myosin heavy
chain were more abundant in the hypoxic group than in the normoxic group. Based upon their low
intensity in 2D-PAGE, however these spots appear to be minor forms of these proteins whose regulation
may differ from the major forms of these contractile proteins.
I also observed an increase in the amounts of fragments of the highly abundant proteins creatine kinase
and myosin (Table 5.2) in hypoxic zebrafish, compared to the normoxic group. The concentrations of
these protein fragments are determined by a balance of synthesis and degradation. Changes in spot
intensity corresponding to intact creatine kinase and myosin were not observed, suggesting that the
expressions of these abundant proteins do not change during hypoxia. Rather, steps in the degradation of
these proteins might be differentially sensitive to hypoxia. Specifically, if the initial steps of degradation
occur, but the complete proteolysis to amino acids is slowed, then intermediate-sized protein fragments
would be expected to accumulate during hypoxia.
In this study, I also observed that a fragment of protein arginine N-methyltransferase was up-regulated by
a factor of 1.5 (Table 5.2). Protein methylation is recognized as a major modification pathway in
regulation of numerous cellular events including cell proliferation, signal transduction, and protein
trafficking.24-26 I also observed that nucleoside diphosphate kinase (NDP kinase) showed higher
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expression by 2.6-fold during hypoxia. NDP kinase catalyzes the exchange of phosphoryl groups between
nucleoside triphosphates and the corresponding diphosphates. The up-reguation of NDP kinase is not well
understood currently and its role in hypoxia warrants further study.
In this analysis, one of most significant findings was that Hb α variants increased in skeletal muscle after
2 days of severe hypoxic exposure (PO2 = 1.9 kPa). Typically, hemoglobin is found in erythrocytes where
it is responsible for binding oxygen at the respiratory surface and delivering it to tissues for aerobic
metabolism. During hypoxia, changes in hemoglobin concentration and oxygen affinity may help to
maintain oxygen delivery to tissues.27 However, Roesner et al. recently showed that mRNA of both Hb α
and β subunits were down-regulated after 48 h hypoxic exposure of adult zebrafish (PO2 = 4.1 kPa).27 Ton
et al. also showed similar changes of Hb mRNA levels in zebrafish embryos using cDNA microarray
technology.17 The discrepancy between my results and those of previous studies could be due to
differences in strain, developmental stage, or tissue sampled, or other experimental conditions, such as
severity and duration of hypoxic exposure. Another possibility is that for Hb α, transcript abundance and
protein levels are poorly correlated, as documented for a number of proteins and cell types.28 Perhaps
mRNA and protein levels are temporally uncoupled, in which an early increase in hemoglobin mRNA
during hypoxia (prior to initial samples in previous studies) results in a sustained increase in protein
levels, even after the transcript levels dropped below normoxic values.
Regardless of reasons for the discrepancy between Hb mRNA and protein levels, the present results
demonstrate strong up-regulation of Hb α protein variants in skeletal muscle from hypoxic zebrafish. At
present, the mechanism underlying this observation is not known. One possibility is that an increase in the
perfusion of muscle microcirculation during hypoxia introduced more blood (thus more Hb) into the
samples, despite taking care to exclude blood, red muscle, and skin during dissection. A second possibility
is that there were no changes in muscle perfusion, but that the small amounts of blood in the samples had
higher hemoglobin content or a different hemoglobin composition during hypoxia. Changes in
hemoglobin concentration and type are both argued to be adaptive responses to hypoxia in a variety of
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animals, including fish.29-32 These scenarios are not mutually exclusive and both would yield altered
hemoglobin composition in samples of skeletal muscle as a result of circulatory responses to hypoxia. A
third explanation for elevated expression of Hb α variants is that these proteins are expressed in the
skeletal muscle during hypoxia. That is, one or both of these novel Hb α subunits could be
muscle-specific proteins that increase oxygen transport intracellularly. Although this role is generally
ascribed to myoglobin, recent discovery of other intracellular globins (cytoglobin27, neuroglobin33 and
globin X34) demonstrates considerable diversity with regard to structure, tissue specificity, and function
among members of the globin gene family. Because the tissue localization of the two Hb α variants
identified here has not been previously described, the possibility that these are muscle-specific forms of
Hb α cannot be ruled out.

Conclusion
Zebrafish adjust to hypoxia via physiological and biochemical responses. Switching from aerobic to
anaerobic energy metabolism under reduced oxygen tension in our study agrees with the cDNA
microarray data of hypoxic zebrafish embryo. Interestingly, modulation of glycogen phosphorylase and
hemoglobin variants during hypoxia is different from the results reported in microarray and RT-PCR
studies. Contrary to the up-regulation of Hb that was observed in our studies, these latter techniques
indicated that gene expression of Hb is down-regulated. The discrepancy of the results acquired from
proteomic and genomic studies reveals the importance of considering all sources of information to
improve the understanding of hypoxic responses.
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Appendix
Table A-1 pI, molecular weight, and the matched sequence to putative intact proteins
Spot
No.

Protein
Identification
(Accession No.)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

1406

nucleoside
diphosphate
kinase-Z2

16/17.2

5.0/6.78

28/27.1

6.2/6.45

28/27.1

6.5/6.45

50/47.4

6.5/6.16

(NP_571002)

1181

triosephosphate
isomerase B
(AAK65202)

1183

triosephosphate
isomerase B
(AAK85202)

Enolase 1, (alpha)
0809
(AAH595511)

99

K.FVQASEDLAK.Q
K.QHYIDLK.D
K.DQPFYAGLVK.Y (61)
R.VMLGETDPFASKPGTIR.G
R.VMLGETDPFASKPGTIR.G
Oxidation (M) (70)
R.GDFCIEVGR.N (43)
R.NLIHGSDSEK.S
K.SAATEVSLWFKPEELVSYR.S (120)
R.SCAQEWIYE.- (27)
K.FFVGGNWK.M
K.LNPDTEVVCGAPTIYLDYAR.S (96)
K.VAKGAFTGEISPAMIK.D
K.GAFTGEISPAMIK.D Oxidation (M)
R.RHVFGESDELIGQK.V
K.VAHALENGLGVIACIGEK.L
K.FIADNVK.D
K.VVLAYEPVWAIGTGK.T
K.TNVSEAVANSVR.I
K.DLDGFLVGGASLKPEFIDIINAK.A (22)
K.SIEELANTLNSAK.L
K.LNPDTEVVCGAPTIYLDYAR.S (72)
K.VAHALENGLGVIACIGEK.L
K.FIADNVK.D
K.TASPQQAQEVHDKLR.Q (31)
K.TNVSEAVANSVR.I
R.IIYGGSVTGGTCK.E
R.AAVPSGASTGIYEALELR.D (123)
K.AVEHINK.T
K.FGANAILGVSLAVCK.A
R.HIADLAGNPEVILPVPAFNVINGGSHAG
NK.L (35)
K.LAMQEFMILPVGASNFK.E
2 Oxidation (M)
R.IGAEVYHNLK.N (60)
K.DATNVGDEGGFAPNILENK.E
K.IVIGMDVAASEFYK.G Oxidation (M)
K.YDLDFK.S (12)
K.VNQIGSVTESLQACK.M
K.MAQTNGWGVMVSHR.S
2 Oxidation (M) (7)
R.SGETEDTFIADLVVGLCTGQIK.T
K.YNQLLR.I (34)
R.FAGKNFR.K

Table A-1 Continued
Spot
No.

Protein
(Acession No.)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

0851

pyruvate kinase,
muscle, b
[zgc:92037]

53/58.8

5.9/6.88

28/21.0

5.5/4.63

(NP_001003488)

1244

fast skeletal myosin
light chain 1a
(NP_956294)

100

R.NTGIVCTLGPASR.S (88)
R.EMILSGMNVAR.L Oxidation (M)
R.EMILSGMNVAR.L 2 Oxidation (M)
R.LNFSHGTHEYHAETIK.S (107)
R.EAIESFGAGTIDYRPVAIALDTK.G (120)
K.GSGTEEVK.L
K.LTLDDKFMDNCDENTLWLDYK.N
Oxidation (M)
K.FMDNCDENTLWLDYK.N
Oxidation (M)
K.VVQQGSHIYVDDGLISLK.V (130)
K.EIGSDFLNCEIENGGMLGSK.K
Oxidation (M)
K.KGVNLPGANVDLPAVSEK.D
K.GVNLPGANVDLPAVSEK.D
K.DLQFGVEQGVDMVFASFIR.K
K.DLQFGVEQGVDMVFASFIR.K
Oxidation (M) (48)
K.AADVHAVR.K
K.AADVHAVRK.V
K.LENHEGVR.K (44)
R.KFDEILEASDGIMVAR.G
R.KFDEILEASDGIMVAR.G
Oxidation (M) (19)
K.FDEILEASDGIMVAR.G Oxidation (M)
R.GDLGIEIPTEK.V
R.IGKPIICATQMLESMIK.K
2 Oxidation (M)
R.AESSDVANAVLDGADCIMLSGETAK.G
Oxidation (M)
K.GEYPIESVLTQHLIAR.E (123)
R.EAEAAMFHR.Q
R.EAEAAMFHR.Q Oxidation (M)
R.QLFEELR.R
R.QLFEELRR.T
R.RTSHLTR.D
R.DPTESVAIGAVEASFK.C
K.KAEPAPAPAPAPEPPK.A
K.AEPAPAPAPAPEPPKADAVDLSGVK.L
K.LDFTQDQMEDYR.E
Oxidation (M) (27)
K.LDFTQDQMEDYREAFLLFDR.V
Oxidation (M)
R.EAFLLFDR.V (62)
R.VGDSKVAYNQIADIMR.A
Oxidation (M)
K.VAYNQIADIMR.A
K.VAYNQIADIMR.A Oxidation (M) (10)
R.ALGQNPTNK.E
K.ILGNPTADDMVNKR.V Oxidation (M)
K.RVDFEGFLPMLQVVINNPNK.A

Table A-1 Continued
Spot
No.

Protein
(Accession No.)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

1244

fast skeletal myosin
light chain 1a

28/21.0

5.5/4.63

95/95.0

6.1/5.22

42/42.2

5.0/5.23

39/39.7

5.1/5.78

(NP_956294)

0231

fast muscle-specific
myosin heavy chain
(AAK73348)

0923

Actin, alpha1,
skeletal muscle
(NP_571666)

1006

Pyruvate
dehydrogenase
(lipoamide) beta
(AAH53233)

101

K.RVDFEGFLPMLQVVINNPNK.A
Oxidation (M)
R.VDFEGFLPMLQVVINNPNK.A
Oxidation (M)
K.ATYDDYVEGLR.V (83)
R.VFDKEGNGTVMGAELR.I
Oxidation (M) (38)
K.EGNGTVMGAELR.I Oxidation (M)
R.IVLSTLGEK.M
R.IEELEEEIEAER.A (67)
R.DLEESTLQHEATAAALR.K (32)
R.LQTENGEFGR.Q
K.EALVSQLTR.G
R.LQGEVEDLMIDVER.A Oxidation (M)
K.SIHVLEK.A
K.DEEMEQIKR.N
R.SRNDALR.I
R.NVQAQLK.D
K.DAQLHLDDAVR.G
R.KVAEQELVDASER.V (4)
K.NLEVTVK.D
K.QLQKLESR.V
R.GADAVKGVR.K
R.LQDLVDK.L
K.AGFAGDDAPR.A
R.AVFPSIVGRPR.H (39)
R.HQGVMVGMGQK.D Oxidation (M)
K.DSYVGDEAQSKR.G
K.IWHHTFYNELR.V (66)
R.VAPEEHPTLLTEAPLNPK.A (77)
R.TTGIVLDAGDGVTHNVPVYEGYALPH
AIMR.L
R.TTGIVLDAGDGVTHNVPVYEGYALPH
AIMR.L Oxidation (M)
R.GYSFVTTAER.E (50)
K.LCYVALDFENEMATAASSSSLEK.S
Oxidation (M)
K.SYELPDGQVITIGNER.F (111)
R.KDLYANNVLSGGTTMYPGIADR.M
K.DLYANNVLSGGTTMYPGIADR.M
K.DLYANNVLSGGTTMYPGIADR.M
Oxidation (M) (43)
K.QEYDEAGPSIVHR.K (108)
K.SAVSAVLR.R
R.DALNQAMDEELERDER.V
Oxidation (M)
R.VFLLGEEVAQYDGAYK.V
K.VSRGLWK.K
K.TYYMSAGLQAVPIVFR.G
K.TYYMSAGLQAVPIVFR.G Oxidation (M)
K.VLSPWNSEDAR.G (29)

Table A-1 Continued
Spot
No.

Protein
(Accession No.)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

1006

Pyruvate
dehydrogenase
(lipoamide) beta

39/39.7

5.1/5.78

95/97.7

6.7/6.11

(AAH53233)

0418

phosphorylase,
glycogen; brain
(NP_997974)

K.DFVIPIGK.A
K.EGIECEVINLR.S (54)
R.SIRPLDADTIETSITK.T
K.TNHLVTVEGGWPQFGVGAEILAR.I (24)
R.IMEGPAFNYLDAPAVR.V
Oxidation (M) (17)
K.DIIFSVK.K
R.HLHFTLVK.D (23)
R.DYYFALAHTVR.D(83)
R.NLAENISR.V
R.LKQEYFVVAATLQDIIR.R
K.AWEITTK.T
R.IHSDIVK.T
K.IGEDFLTDLFQLR.K
R.IHEYKR.Q
K.VIFLENYR.V (28)

pH 7-11

0713

phosphoglycerate
mutase 2 (muscle)

30/29.0

9.0/8.83

0909

novel protein similar
to zebrafish
hemoglobin
alpha-adult 1 (hbaa1)
(CAE48986)

15/15.5

8.0/7.98

0904

novel protein similar
to zebrafish
hemoglobin
alpha-adult 1 (hbaa1)
(CAE48986)

15/15.5

9.0/8.88

(NP_957318)
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R.HGESSWNQENR.F (82)
R.FCGWFDADLSEK.G 938)
K.GLEEAKR.G
K.DAGMKFDVCYTSVLK.R
Oxidation (M)
K.FDVCYTSVLK.R
K.FDVCYTSVLKR.A
K.TLWTIMEGTDQMWVPVVR.T
K.TLWTIMEGTDQMWVPVVR.T
Oxidation (M)
R.HYGGLTGLNK.A (53)
R.SFDIPPPPMDKDHPYHK.I
Oxidation (M)
K.EGELPICESLK.D
K.EGELPICESLKDTIAR.A (101)
K.DTIARALPFWNEVIVPEIK.A
R.ALPFWNEVIVPEIK.A (36)
K.NVIIAAHGNSLR.G (105)
K.DLKPIKPMQFLGDEETVR.K
Oxidation (M)
K.DLKPIKPMQFLGDEETVRK.A
Oxidation (M)
R.KAMEAVAAQGK.V Oxidation (M)
K.ADEIGAEALAR.M
K.TYFSHWSDLSPGSGPVK.K
K.TYFSHWSDLSPGSGPVKK.H (70)
K.IDDLVGGLAALSELHAFK.L (112)
K.LRVDPANFK.I
K.FFNNLALALSEK.Y
K.ADEIGAEALAR.M (70)
K.TYFSHWSDLSPGSGPVK.K
K.TYFSHWSDLSPGSGPVKK.H (83)
K.IDDLVGGLAALSELHAFK.L (99)
K.LRVDPANFK.I
K.FFNNLALALSEK.Y (19)

Table A-1 Continued
Spot
No.

Protein
Identification

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 7-11

0586

aldolase A
fructose-bisphosphate

40/40.2

9.0/8.45

32/33.4

9.5/8.66

28/28.3

9.6/9.19

(NP_998380)

0699

hydroxyacyl-Coenzy
me A dehydrogenase
(NP_001003515)

0747

ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit b,
isoform 1
(AAH83308)
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-.MPHAYPFLSPDQKK.E
M.PHAYPFLSPDQK.K
K.ELSDIAQR.I
K.ELSDIAQRIVAPGK.G
R.FQSINAENTEENRR.L (46)
R.QLLFTADDR.I
R.IKPCIGGVILFHETLYQK.T
R.GMVVGIKVDK.G Oxidation (M)
K.VDKGVVPLAGTNGETTTQGLDGLYER.
C
K.GVVPLAGTNGETTTQGLDGLYER.C
(79)
K.ITPTTPSNLAIIENANVLAR.Y (110)
R.YASICQMHGIVPIVEPEILPDGDHDLKR.
C Oxidation (M)
K.YSPQEIAMATVTALR.R
K.YSPQEIAMATVTALR.R Oxidation (M)
K.YSPQEIAMATVTALRR.T
K.YSPQEIAMATVTALRR.T
Oxidation (M)
K.GDTGAAAGESLFVANHAY.- (24)
K.SAKGIENSLK.R
K.FAEKPEDGEAFVQK.V
K.VAPEHTIFASNTSSLPIADIASCTAR.L
(48)
K.TPATSQQTFDALLEFSK.A
K.DTPGFIVNR.L (38)
R.LLVPYMLEAVR.L (23)
R.LLVPYMLEAVR.L Oxidation (M)
K.DPDNPLFAPSPLLNK.L
K.TGEGFYK.H
R.SMLFDAK.R Oxidation (M)
R.NNVAMLLEINYR.E
K.RLDYQVELQNLHR.R (51)
R.LDYQVELQNLHR.R (73)
R.LDYQVELQNLHRR.M
K.SITPQQEK.E

Table A-2 pI, molecular weight, and the matched sequence to putative protein fragments
Spot
No.

Protein
(Accession No)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH4-7

1089

creatine kinase,
muscle

35/43.0

6.6/6.32

35/43.0

6.6/6.32

35/43.0

6.6/6.32

80/125.2

6.0/6.21

(NP_571007)

1130

creatine kinase,
muscle
(NP_571007)

1077

creatine kinase,
muscle
(NP_571007)

0611

myosin heavy chain 4
[Wu:fi38g05]
(AAH44194)

104

M.PFGNTHNNFK.L
K.LNYSVDEEYPDLSK.H (70)
K.DLFDPVISDR.H (43)
K.TDLNFENLK.G (53)
K.GGDDLDPNYVLSSR.V (112)
K.GYALPPHNSR.G (50)
K.LSVEALSSLDGEFK.G (108)
K.GKYYPLK.S
R.GIWHNENK.T
K.TFLVWVNEEDHLR.V (102)
K.RFCVGLQR.I
R.FCVGLQR.I (38)
K.FEEILTR.L
M.PFGNTHNNFK.L
K.LNYSVDEEYPDLSK.H (47)
K.HNNHMAK.V Oxidation (M)
K.DLFDPVISDR.H (44)
K.TDLNFENLK.G
K.GGDDLDPNYVLSSR.V (89)
K.GYALPPHNSR.G (53)
K.LSVEALSSLDGEFK.G (113)
K.GKYYPLK.S
K.SMTDAEQEQLIADHFLFDKPVSPLLL
AAGMAR.D 2 Oxidation (M)
R.GIWHNENK.T
K.TFLVWVNEEDHLR.V (102)
K.GGNMKEVFK.R
K.GGNMKEVFK.R Oxidation (M)
R.FCVGLQR.I (37)
R.IEEIFKK.H (27)
K.FEEILTR.L
K.LMVEMEK.K Oxidation (M)
K.HNNHMAK.V
K.GGDDLDPNYVLSSR.V (109)
R.SIKGYALPPHNSR.G
K.GYALPPHNSR.G
K.TFLVWVNEEDHLR.V (122)
K.LMVEMEKK.L
K.LEKGESIDSMIPAQK.- Oxidation (M)
R.MEAPPHIFSVSDNAYQFMLTDR.E
Oxidation (M)
R.MEAPPHIFSVSDNAYQFMLTDR.E
2 Oxidation (M)
K.RVIQYFATVAVQGGDK.K
R.VIQYFATVAVQGGDK.K (106)
K.MQGSLEDQIIAANPLLEAYGNAK.T
Oxidation (M) (53)
R.IHFGTTGK.L
K.LASADIETYLLEK.S (65)
R.VTFQLPDER.G (42)
K.FTGAVLHHGNMK.F
Oxidation (M) (41)
K.VGNEFVTK.G
K.GQTVPQVYNSVSALSK.S (68)

Table A-2 Continued
Spot
No.

Protein
(Accession No)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

0611

myosin heavy chain 4
[Wu:fi38g05]

80/125.2

6.0/6.21

80/125.8

6.5/5.56

96/125.2

6.0/6.21

80/125.2

6.6/6.21

96/222.8

6.1/5.55

(AAH91662)

0571

myosin binding
protein C, fast-type
[Zgc:110761]
(AAH91662)

0367

myosin heavy chain 4
[Wu:fi38g05]
(AAH44194)

0553

myosin heavy chain 4
[Wu:fi38g05]
(AAH44194)

0349

myosin, heavy
polypeptide 2, fast
muscle specific
(NP_694514)
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K.MFLWMVIR.I
K.MFLWMVIR.I Oxidation (M)
K.MFLWMVIR.I 2 Oxidation (M)
K.LQQFFNHHMFVLEQEEYKK.E
Oxidation (M) (1)
K.LYDQHLGK.C (39)
K.AEAHFSLVHYAGTVDYNVNGWLDK.
N
K.NKDPLNESVVQLYQK.S
R.AYLMRR.E Oxidation (M)
R.KLEGDLK.L
K.WMDLGSK.A
K.FSEAFLR.R (12)
R.RLESAYSVNK.G
K.YIMEADGNIR.T Oxidation (M)
K.EPPITITK.L
K.LLDDYHVVVGER.V (62)
K.LNFLEIK.I
K.DLSCFIIEGAER.E
K.FDGGAPLK.G
K.GSSRWTK.L
R.SPPALLGQPVTVR.E (49)
K.FTAPLVDR.A (18)
R.AVTIGYSTAISCAVR.A
K.MIIGDDPK.F
R.VIQYFATVAVQGGDK.K (22)
R.VTFQLPDER.G (27)
K.ISYLLGSNSAELLKALCYPR.V
K.LYDQHLGK.C
R.AYLMRR.E
R.AYLMRR.E Oxidation (M)
K.SKIQLEAK.L
R.KLEGDLK.L
R.ENQSVLITGESGAGK.T
R.VIQYFATVAVQGGDK.K
R.IHFGTTGK.L
R.VTFQLPDER.G (43)
R.ILYGDFK.Q
R.AYLMRR.E Oxidation (M)
K.HWPWMK.V
K.CKEDLVK.A
R.MDLERAK.R
R.KLEGDLK.L
K.LAQESIMDLENDKQQSEEK.K
R.ENQSVLITGESGAGK.T
R.VIQYFATVAVQGGDK.K (17)
R.VTFQLPDER.G (42)
K.GQTVPQVYNSVSALSKSIYER.M
R.MFLWMVIR.I 2 Oxidation (M)
R.AYLMRR.E Oxidation (M)
K.HWPWMK.V Oxidation (M)
K.LAQESIMDLENDKQQSEEK.I
K.QRADLSR.E
R.SRNDALR.I

Table A-2 Continued
Spot
No.

Protein
(Accession No)

0349

myosin, heavy
polypeptide 2, fast
muscle specific
(NP_694514)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH 4-7

1221

protein arginine
N-methyltransferase 1

96/222.8

6.1/5.55

30/40.0

5.9/5.47

80/95.0

5.0/5.22

(NP_956944)

0618

fast muscle-specific
myosin heavy chain
(AAK73348)
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R.NVQAQLK.D
K.DAQLHLDDAVRGQEDMK.E
K.NLEVTVK.D
R.LQDLVDK.L
-.MEVSQGESSAKPAAEDMTSK.D
R.NSMFHNK.H
R.NSMFHNK.H Oxidation (M)
R.NSMFHNKHLFR.D
K.KVIGIECSSISDYAVK.I
R.QYKDYK.I
K.IHWWENVYGFDMSCIK.E
Oxidation (M)
K.NNRDLDFTVDIDFK.G
R.DLDFTVDIDFKGQLCEVSK.T
K.TSEYRMR.K.QRADLSR.E
R.EQFEEEQEAK.A
K.ANSEVAQWR.T (58)
R.TKYETDAIQR.T
R.LQEAEEQIEAVNSK.C
R.LQGEVEDLMIDVER.A
R.LQGEVEDLMIDVER.A
Oxidation (M) (53)
K.NSYEETLDQLETLK.R
K.NSYEETLDQLETLKR.E (92)
K.NLQQEISDLTEQLGETGK.S (104)
K.AEIQTALEEAEGTLEHEESK.I
R.VQLELNQVK.G
R.VTEAMQSTLDSEVR.S
Oxidation (M)
K.KMEGDLNEMEIQLSHANR.Q
2 Oxidation (M)
K.MEGDLNEMEIQLSHANR.Q
K.MEGDLNEMEIQLSHANR.Q
2 Oxidation (M)
R.NVQAQLK.D
K.DAQLHLDDAVR.G (84)
R.GQEDMKEQVAMVER.R
2 Oxidation (M)
R.NTLMQSEIEELR.A
R.NTLMQSEIEELR.A Oxidation (M) (4)
R.AALEQTER.G
R.KVAEQELVDASER.V
K.VAEQELVDASER.V (86)
R.VGLLHSQNTSLLNTK.K (95)
K.EQDTSAHLER.M
K.NLEVTVK.D
R.VRELESEVEAEQR.R
R.ELESEVEAEQR.R
R.LQDLVDK.L
R.KVQHELEEAEER.A
K.VQHELEEAEER.A

Table A-2 Continued
Spot
No.

Protein
(Accession No)

Mr (kDa)
obs/pred

pI
obs/pred

Matched Sequence (peptide ion score)

pH4-7

1188

actin, alpha 1,
skeletal muscle

30/42.3

4.8/5.23

(NP_571666)

1322

mitochondrial ATP
synthase

20/40.0

5.8/9.18

70/36.9

6.5/6.27

(AAS49605)

0775

phosphorylase,
glycogen (muscle) b
[MGC63642]
(NP_956766)

K.AGFAGDDAPR.A (53)
R.AVFPSIVGRPR.H
K.IWHHTFYNELR.V (68)
R.VAPEEHPTLLTEAPLNPK.A (102)
R.GYSFVTTAER.E (63)
K.LCYVALDFENEMATAASSSSLEK.S
Oxidation (M)
K.SYELPDGQVITIGNER.F (115)
R.NVQAEEMVEFSSGLK.G
Oxidation (M) (52)
K.GMSLNLEPDNVGVVVFGNDK.L
Oxidation (M) (43)
R.TGAIVDVPVGEELLGR.V (121)
R.EPMQTGIK.A Oxidation (M)
K.AVDSLVPIGR.G (41)
R.ELIIGDR.Q.
K.TAIAIDTIINQK.R
R.LTDADAMK.Y
R.LTDADAMK.Y Oxidation (M)
M.SKPLTDQEK.R
K.DRNVATK.R
R.DYYFALAHTVR.D (57)
R.YEFGIFNQK.I
R.TISQYAR.E

pH7-11

1188

actin, alpha 1,
skeletal muscle

30/42.3

4.8/5.23

(NP_571007)

1322

mitochondrial ATP
synthase

20/40.0

5.8/9.18

(NP_955858)
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K.AGFAGDDAPR.A (53)
R.AVFPSIVGRPR.H
K.IWHHTFYNELR.V (68)
R.VAPEEHPTLLTEAPLNPK.A (102)
R.GYSFVTTAER.E (63)
K.LCYVALDFENEMATAASSSSLEK.S
Oxidation (M)
K.SYELPDGQVITIGNER.F (115)
R.NVQAEEMVEFSSGLK.G
Oxidation (M) (52)
K.GMSLNLEPDNVGVVVFGNDK.L
Oxidation (M) (43)
R.TGAIVDVPVGEELLGR.V (121)
R.EPMQTGIK.A Oxidation (M)
K.AVDSLVPIGR.G (41)
R.ELIIGDR.Q.
K.TAIAIDTIINQK.R
R.LTDADAMK.Y
R.LTDADAMK.Y Oxidation (M)
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